[
  {
    "nctId": "NCT04699188",
    "avg_inclusion_score": 0.875,
    "avg_exclusion_score": 1.0,
    "avg_overall_score": 0.9375,
    "trial": {
      "clean_text": "#briefTitle\nStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation\n\n#officialTitle\nA Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation\n\n#briefSummary\nThis is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.\n\n#conditions\nKRAS G12C Mutant Solid Tumors\nCarcinoma, Non-Small-Cell Lung\nCarcinoma, Colorectal\nCancer of Lung\nCancer of the Lung\nLung Cancer\nNeoplasms, Lung\nNeoplasms, Pulmonary\nPulmonary Cancer\nPulmonary Neoplasms\n\n",
      "briefTitle": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "officialTitle": "A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "briefSummary": "This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.",
      "detailedDescription": null,
      "conditions": [
        "KRAS G12C Mutant Solid Tumors",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Colorectal",
        "Cancer of Lung",
        "Cancer of the Lung",
        "Lung Cancer",
        "Neoplasms, Lung",
        "Neoplasms, Pulmonary",
        "Pulmonary Cancer",
        "Pulmonary Neoplasms"
      ],
      "armGroups": [
        {
          "label": "Arm A",
          "type": "EXPERIMENTAL",
          "description": "JDQ443",
          "interventionNames": [
            "Drug: JDQ443"
          ]
        },
        {
          "label": "Arm B",
          "type": "EXPERIMENTAL",
          "description": "JDQ443 in combination with TNO155",
          "interventionNames": [
            "Drug: JDQ443",
            "Drug: TNO155"
          ]
        },
        {
          "label": "Arm C",
          "type": "EXPERIMENTAL",
          "description": "JDQ443 in combination with tislelizumab",
          "interventionNames": [
            "Drug: JDQ443",
            "Biological: tislelizumab"
          ]
        },
        {
          "label": "Arm D",
          "type": "EXPERIMENTAL",
          "description": "JDQ443 in combination with TNO155 and tislelizumab",
          "interventionNames": [
            "Drug: JDQ443",
            "Drug: TNO155",
            "Biological: tislelizumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "JDQ443",
          "description": "KRAS G12C inhibitor",
          "armGroupLabels": [
            "Arm A",
            "Arm B",
            "Arm C",
            "Arm D"
          ]
        },
        {
          "type": "DRUG",
          "name": "TNO155",
          "description": "SHP2 inhibitor",
          "armGroupLabels": [
            "Arm B",
            "Arm D"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "tislelizumab",
          "description": "Anti PD1 antibody",
          "armGroupLabels": [
            "Arm C",
            "Arm D"
          ]
        }
      ],
      "primaryOutcomes": [
        {
          "measure": "Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment",
          "description": "A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment",
          "timeFrame": "21 days"
        },
        {
          "measure": "Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)",
          "description": "All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs).",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation: Frequency of dose interruptions and reductions, by treatment",
          "description": "Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation: Dose intensity by treatment",
          "description": "Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of treatment.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatment",
          "description": "Overall response rate is defined as the proportion of patients with a BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI). Applies to all groups except the brain metastasis group.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: Overall intracranial response rate (OIRR) per mRANO-BM",
          "description": "OIRR per mRANO-BM is defined as the proportion of participants with a best overall intracranial response (BOIR) of CR or PR according to mRANO-BM criteria, and will be summarized along with the corresponding 90% and 95% exact CI. Applies to brain metastasis group only.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: Incidence and severity of AEs and SAEs",
          "description": "All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs). Applies to JDQ443 dose randomization group only.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: frequency of dose interruptions and reductions, by treatment",
          "description": "Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions. Applies to JDQ443 dose randomization group only.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: Dose intensity by treatment",
          "description": "Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of treatment. Applies to JDQ443 dose randomization group only",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only)",
          "description": "Overall response rate is defined as the proportion of patients with BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI). Applies to JDQ443 dose randomization group only",
          "timeFrame": "24 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Dose Escalation and Expansion: ORR per RECIST v1.1",
          "description": "Overall response rate is defined as the proportion of patients with a BOR of CR or PR according to RECIST 1.1, and will be summarized along with the corresponding 95% exact binomial confidence interval (CI)",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Best Overall Response (BOR) per RECIST v1.1",
          "description": "BOR is defined as the best overall confirmed response recorded from the start of the treatment until disease progression/recurrence.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Progression-free survival (PFS) per RECIST v1.1, Overall Survival (OS)",
          "description": "Per RECIST 1.1, PFS is defined as the time from the date of start of treatment to the date of the first documented progression, or death. If patient has not had an event, PFS will be censored at the date of last adequate tumor assessment. PFS will be summarized using the Kaplan-Meier method, along with 95% CI",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Duration of Response (DOR) per RECIST v1.1",
          "description": "Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause. Estimates will use Kaplan-Meier method, and median DOR and corresponding 95% CI will be presented.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Disease Control Rate (DCR) per RECIST v1.1",
          "description": "The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease. It will be summarized along with the corresponding 95% exact CI",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Plasma or serum concentration vs time profiles (AUC) by treatment",
          "description": "AUC is defined as area under the plasma or serum concentration versus time curve after a dose of JDQ443, TNO155 and tislelizumab",
          "timeFrame": "Up to 24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Plasma concentration (Cmax) by treatment",
          "description": "Cmax is defined as the maximum observed plasma or serum drug concentration after single dose administration.",
          "timeFrame": "Up to 24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Time to achieve Cmax (Tmax) by treatment",
          "description": "Tmax is defined as the time to reach maximum plasma or serum drug concentration after single dose administration.",
          "timeFrame": "Up to 24 months"
        },
        {
          "measure": "Dose Escalation and Expansion: Antidrug antibody (ADA) incidence by treatment",
          "description": "To evaluate the immunogenicity of tislelizumab when dosed in combination with JDQ443 and/or TNO155 - only applicable to Arms C and D",
          "timeFrame": "Up to 24 months"
        },
        {
          "measure": "Dose Expansion: Dose intensity by treatment",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Expansion: Frequency of dose interruptions and reductions, by treatment",
          "description": "Tolerability of study drug will be assessed by summarizing the number of and reason for dose delays and dose reductions.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Expansion: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment",
          "description": "A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment",
          "timeFrame": "21 days"
        },
        {
          "measure": "Dose Expansion: Incidence and severity of AEs and SAEs by treatment",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: Intracranial disease control rate (IDCR) per mRANO-BM",
          "description": "IDCR is the proportion of participants with a confirmed BOIR of CR or PR or SD (or non-CR/non-PD) per mRANO-BM criteria. It will be summarized along with the corresponding 90% and 95% CI. Applies to the brain metastasis group only.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: Best overall intracranial response (BOIR) per mRANO-BM",
          "description": "BOIR is defined as the best overall confirmed response recorded from the start of the treatment until disease progression/recurrence per mRANO-BM, or until patient comes off study, whichever comes first. BOIR will be summarized along with the corresponding 95% exact CI. Applies to the brain metastasis group only.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: Intracranial progression free survival (IPFS) per mRANO-BM",
          "description": "IPFS is defined as the time from the date of start of treatment to the date of the first documented progression per mRANO-BM, or death due to any cause. If a patient has not had an event, IPFS will be censored at the date of last adequate tumor assessment. IPFS will be summarized using the Kaplan-Meier method. Median IPFS and IPFS probability at pre specified time-points will be presented along with 95% CI. Applies to the brain metastasis group only.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose expansion: Duration of intracranial response (DOIR) per mRANO-BM",
          "description": "DOIR is defined as the time from the date of first documented intracranial response of either CR or PR to the date of the first documented intracranial progression as per mRANO-BM criteria as assessed by central review or date of death due to underlying cause of cancer. DOIR will be summarized using the KM method if data permit. Median DOIR, with corresponding 95% CI. KM estimates for DOIR proportions at specific time points, along with 95% CI will also be provided. Applies to the brain metastasis group only.",
          "timeFrame": "24 months"
        }
      ],
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies\n* ECOG Performance Status of 0 or 1\n* At least one measurable lesion as defined by RECIST 1.1\n* Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion\n\nExclusion Criteria:\n\n* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations\n* Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible\n* Clinically significant cardiac disease or risk factors at screening\n* A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply.",
      "nctId": "NCT04699188",
      "overallStatus": "RECRUITING",
      "keywords": [
        "KRAS",
        "KRAS G12C",
        "Metastatic cancer",
        "Advanced cancer",
        "Enzyme inhibitor",
        "PD-1",
        "SHP2",
        "Targeted therapy",
        "Non-small-cell lung cancer",
        "colorectal cancer",
        "Molecular mechanisms of pharmacological action"
      ],
      "locations": [
        {
          "facility": "Emory University School of Medicine/Winship Cancer Institute Winship Cancer Center",
          "status": "RECRUITING",
          "city": "Atlanta",
          "state": "Georgia",
          "zip": "30322",
          "country": "United States",
          "contacts": [
            {
              "name": "Obi Okafor",
              "role": "CONTACT",
              "email": "aookafo@emory.edu"
            },
            {
              "name": "Conor E. Steuer",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 33.749,
            "lon": -84.38798
          }
        },
        {
          "facility": "Massachusetts General Hospital Cancer Center",
          "status": "RECRUITING",
          "city": "Boston",
          "state": "Massachusetts",
          "zip": "02114",
          "country": "United States",
          "contacts": [
            {
              "name": "Rebecca Heist",
              "role": "CONTACT",
              "email": "rheist@partners.org"
            },
            {
              "name": "Rebecca Heist",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 42.35843,
            "lon": -71.05977
          }
        },
        {
          "facility": "Washington Uni School of Med .",
          "status": "WITHDRAWN",
          "city": "Saint Louis",
          "state": "Missouri",
          "zip": "63110",
          "country": "United States",
          "geoPoint": {
            "lat": 38.62727,
            "lon": -90.19789
          }
        },
        {
          "facility": "Providence Cancer Center",
          "status": "RECRUITING",
          "city": "Portland",
          "state": "Oregon",
          "zip": "97213",
          "country": "United States",
          "contacts": [
            {
              "name": "Teresa Song",
              "role": "CONTACT",
              "phone": "503-215-2691",
              "email": "teresa.song@providence.org"
            },
            {
              "name": "Rachel Sanborn",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 45.52345,
            "lon": -122.67621
          }
        },
        {
          "facility": "Hillman Cancer Center",
          "status": "RECRUITING",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15232",
          "country": "United States",
          "contacts": [
            {
              "name": "Lorenzo Sellitto",
              "role": "CONTACT",
              "phone": "412-647-8569",
              "email": "sellittol@upmc.edu"
            },
            {
              "name": "Timothy Burns",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        },
        {
          "facility": "Uni of TX MD Anderson Cancer Cntr Dept of MD Anderson CancerCent",
          "status": "RECRUITING",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "contacts": [
            {
              "name": "Rebecca Okumah",
              "role": "CONTACT",
              "phone": "+1 713 745 3039",
              "email": "rokumah@mdanderson.org"
            },
            {
              "name": "Marcelo Vailati Negrao",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Melbourne",
          "state": "Victoria",
          "zip": "3000",
          "country": "Australia",
          "geoPoint": {
            "lat": -37.814,
            "lon": 144.96332
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Leuven",
          "zip": "3000",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.87959,
            "lon": 4.70093
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Montreal",
          "state": "Quebec",
          "zip": "H2W 1T8",
          "country": "Canada",
          "geoPoint": {
            "lat": 45.50884,
            "lon": -73.58781
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Fuzhou",
          "state": "Fujian",
          "zip": "350014",
          "country": "China",
          "geoPoint": {
            "lat": 26.06139,
            "lon": 119.30611
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Guangzhou",
          "state": "Guangdong",
          "zip": "51000",
          "country": "China",
          "geoPoint": {
            "lat": 23.11667,
            "lon": 113.25
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Nanchang",
          "state": "Jiangxi",
          "zip": "330006",
          "country": "China",
          "geoPoint": {
            "lat": 28.68396,
            "lon": 115.85306
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Beijing",
          "zip": "100036",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Copenhagen",
          "zip": "DK-2100",
          "country": "Denmark",
          "geoPoint": {
            "lat": 55.67594,
            "lon": 12.56553
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Lyon",
          "zip": "69373",
          "country": "France",
          "geoPoint": {
            "lat": 45.74848,
            "lon": 4.84669
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Marseille",
          "zip": "13273",
          "country": "France",
          "geoPoint": {
            "lat": 43.29551,
            "lon": 5.38958
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Villejuif",
          "zip": "94800",
          "country": "France",
          "geoPoint": {
            "lat": 48.7939,
            "lon": 2.35992
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Dresden",
          "zip": "01307",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.05089,
            "lon": 13.73832
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Essen",
          "zip": "45147",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.45657,
            "lon": 7.01228
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Freiburg",
          "zip": "79106",
          "country": "Germany",
          "geoPoint": {
            "lat": 47.9959,
            "lon": 7.85222
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Koeln",
          "zip": "50937",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.93333,
            "lon": 6.95
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Hong Kong",
          "country": "Hong Kong",
          "geoPoint": {
            "lat": 22.27832,
            "lon": 114.17469
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Brescia",
          "state": "BS",
          "zip": "25123",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.53558,
            "lon": 10.21472
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Milano",
          "state": "MI",
          "zip": "20133",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Milano",
          "state": "MI",
          "zip": "20162",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Nagoya",
          "state": "Aichi",
          "zip": "466 8560",
          "country": "Japan",
          "geoPoint": {
            "lat": 35.18147,
            "lon": 136.90641
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Kashiwa",
          "state": "Chiba",
          "zip": "277 8577",
          "country": "Japan",
          "geoPoint": {
            "lat": 35.86224,
            "lon": 139.97732
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Yokohama-city",
          "state": "Kanagawa",
          "zip": "241-8515",
          "country": "Japan",
          "geoPoint": {
            "lat": 35.43333,
            "lon": 139.65
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Osaka-city",
          "state": "Osaka",
          "zip": "541-8567",
          "country": "Japan",
          "geoPoint": {
            "lat": 34.69374,
            "lon": 135.50218
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Chuo ku",
          "state": "Tokyo",
          "zip": "104 0045",
          "country": "Japan",
          "geoPoint": {
            "lat": 35.57779,
            "lon": 139.71685
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Koto ku",
          "state": "Tokyo",
          "zip": "135 8550",
          "country": "Japan",
          "geoPoint": {
            "lat": 35.66667,
            "lon": 139.81718
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Osaka",
          "zip": "545-8586",
          "country": "Japan",
          "geoPoint": {
            "lat": 34.69374,
            "lon": 135.50218
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "03722",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Amsterdam",
          "zip": "1066 CX",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.37403,
            "lon": 4.88969
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Singapore",
          "zip": "119074",
          "country": "Singapore",
          "geoPoint": {
            "lat": 1.28967,
            "lon": 103.85007
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Singapore",
          "zip": "168583",
          "country": "Singapore",
          "geoPoint": {
            "lat": 1.28967,
            "lon": 103.85007
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Malaga",
          "state": "Andalucia",
          "zip": "29010",
          "country": "Spain",
          "geoPoint": {
            "lat": 36.72016,
            "lon": -4.42034
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Barcelona",
          "state": "Catalunya",
          "zip": "08035",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Hospitalet de LLobregat",
          "state": "Catalunya",
          "zip": "08907",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.35967,
            "lon": 2.10028
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Valencia",
          "state": "Comunidad Valenciana",
          "zip": "46010",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.46975,
            "lon": -0.37739
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Santiago De Compostela",
          "state": "Galicia",
          "zip": "15706",
          "country": "Spain",
          "geoPoint": {
            "lat": 42.88052,
            "lon": -8.54569
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28050",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Tainan",
          "zip": "70403",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 22.99083,
            "lon": 120.21333
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Taipei",
          "zip": "10002",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 25.04776,
            "lon": 121.53185
          }
        }
      ],
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies\n* ECOG Performance Status of 0 or 1\n* At least one measurable lesion as defined by RECIST 1.1\n* Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion\n\nExclusion Criteria:\n\n* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations\n* Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible\n* Clinically significant cardiac disease or risk factors at screening\n* A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": [
          "ADULT",
          "OLDER_ADULT"
        ]
      },
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ]
    },
    "structured_criteria": {
      "inclusion": {
        "Inclusion Criteria:": [
          "Patients who meet all of the following criteria are eligible for trial participation: ",
          [
            "* Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies",
            "* ECOG Performance Status of 0 or 1",
            "* At least one measurable lesion as defined by RECIST 1.1",
            "* Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion"
          ]
        ]
      },
      "exclusion": {
        "Exclusion Criteria:": [
          "Patients who meet any of the following criteria are not eligible for trial participation: ",
          [
            "* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations",
            "* Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible",
            "* Clinically significant cardiac disease or risk factors at screening",
            "* A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply."
          ]
        ]
      }
    },
    "results_inclusion": [
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "* Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies",
          "* ECOG Performance Status of 0 or 1",
          "* At least one measurable lesion as defined by RECIST 1.1",
          "* Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each criterion based on the provided patient information.\n\n1. **Criterion 1: \u00ab* Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies\u00bb**\n   - The patient is diagnosed with metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC).\n   - The patient has received standard of care treatments including chemotherapy and immunotherapy.\n   - Therefore, the patient meets this criterion.\n   - **Decision: True**\n\n2. **Criterion 2: \u00ab* ECOG Performance Status of 0 or 1\u00bb**\n   - The patient's ECOG Performance Status is 1.\n   - Therefore, the patient meets this criterion.\n   - **Decision: True**\n\n3. **Criterion 3: \u00ab* At least one measurable lesion as defined by RECIST 1.1\u00bb**\n   - The patient has multiple measurable lesions, including a mass in the left lung and new nodules in the right lung.\n   - Therefore, the patient meets this criterion.\n   - **Decision: True**\n\n4. **Criterion 4: \u00ab* Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion\u00bb**\n   - There is no information provided about prior treatment with a KRAS G12C inhibitor.\n   - Therefore, it is unclear if the patient meets this criterion.\n   - **Decision: ?**",
          "criteria_decision": {
            "explanation": [
              "The patient has metastatic KRAS G12C mutant NSCLC and has received standard of care treatments.",
              "The patient's ECOG Performance Status is 1.",
              "The patient has multiple measurable lesions.",
              "There is no information provided about prior treatment with a KRAS G12C inhibitor."
            ],
            "criteria_decision": [
              true,
              true,
              true,
              "?"
            ]
          }
        }
      ]
    ],
    "results_exclusion": [
      [
        "Exclusion Criteria:",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations",
          "* Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible",
          "* Clinically significant cardiac disease or risk factors at screening",
          "* A medical condition that results in increased photosensitivity Other protocol-defined inclusion/exclusion criteria may apply."
        ],
        {
          "reasoning": "```json\n{\n    \"explanation\": [\n        \"The patient has a KRAS G12C mutation, which is explicitly mentioned as an exception in the exclusion criteria. Therefore, the patient is eligible based on this criterion.\",\n        \"The patient had an MRI scan of the brain conducted on March 12, 2024, which showed no evidence of metastatic disease. Therefore, the patient is eligible based on this criterion.\",\n        \"The patient has controlled hypertension, type 2 diabetes mellitus, hyperlipidemia, and mild COPD. There is no mention of clinically significant cardiac disease or risk factors that would make the patient ineligible. Therefore, the patient is eligible based on this criterion.\",\n        \"There is no mention of any medical condition that results in increased photosensitivity in the patient information. Therefore, the patient is eligible based on this criterion.\"\n    ],\n    \"criteria_decision\": [true, true, true, true]\n}\n```",
          "criteria_decision": {
            "explanation": [
              "The patient has a KRAS G12C mutation, which is explicitly mentioned as an exception in the exclusion criteria. Therefore, the patient is eligible based on this criterion.",
              "The patient had an MRI scan of the brain conducted on March 12, 2024, which showed no evidence of metastatic disease. Therefore, the patient is eligible based on this criterion.",
              "The patient has controlled hypertension, type 2 diabetes mellitus, hyperlipidemia, and mild COPD. There is no mention of clinically significant cardiac disease or risk factors that would make the patient ineligible. Therefore, the patient is eligible based on this criterion.",
              "There is no mention of any medical condition that results in increased photosensitivity in the patient information. Therefore, the patient is eligible based on this criterion."
            ],
            "criteria_decision": [
              true,
              true,
              true,
              true
            ]
          }
        }
      ]
    ]
  },
  {
    "nctId": "NCT05358249",
    "avg_inclusion_score": 1.0,
    "avg_exclusion_score": 0.9,
    "avg_overall_score": 0.9375,
    "trial": {
      "clean_text": "#briefTitle\nPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation\n\n#officialTitle\nKontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation\n\n#briefSummary\nThis is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.\n\n#detailedDescription\nJDQ443 will be considered \"backbone\" treatment in this trial and combined with selected therapies, or \"partner(s)\". The combination of a backbone and a partner will constitute a treatment arm. After dose escalation, treatment arms that reach a maximum tolerated dose /recommended dose and are determined to be safe may, but are not required to, proceed to Phase II to further explore safety, tolerability, and anti-tumor activity.\n\n#conditions\nKRAS G12C Mutant Solid Tumors\nCarcinoma, Non-Small Cell Lung\nCarcinoma, Non-Small-Cell Lung\nNon-Small Cell Lung Cancer\nNon-Small Cell Lung Carcinoma\nNonsmall Cell Lung Cancer\nColorectal Cancer\nColorectal Carcinoma\nColorectal Neoplasms\nColorectal Tumors\nNeoplasms, Colorectal\n\n",
      "briefTitle": "Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "officialTitle": "KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "briefSummary": "This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.",
      "detailedDescription": "JDQ443 will be considered \"backbone\" treatment in this trial and combined with selected therapies, or \"partner(s)\". The combination of a backbone and a partner will constitute a treatment arm. After dose escalation, treatment arms that reach a maximum tolerated dose /recommended dose and are determined to be safe may, but are not required to, proceed to Phase II to further explore safety, tolerability, and anti-tumor activity.",
      "conditions": [
        "KRAS G12C Mutant Solid Tumors",
        "Carcinoma, Non-Small Cell Lung",
        "Carcinoma, Non-Small-Cell Lung",
        "Non-Small Cell Lung Cancer",
        "Non-Small Cell Lung Carcinoma",
        "Nonsmall Cell Lung Cancer",
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Colorectal Neoplasms",
        "Colorectal Tumors",
        "Neoplasms, Colorectal"
      ],
      "armGroups": [
        {
          "label": "JDQ443+trametinib",
          "type": "EXPERIMENTAL",
          "description": "JDQ443 in combination with trametinib",
          "interventionNames": [
            "Drug: JDQ443",
            "Drug: trametinib"
          ]
        },
        {
          "label": "JDQ443+ribociclib",
          "type": "EXPERIMENTAL",
          "description": "JDQ443 in combination with ribociclib",
          "interventionNames": [
            "Drug: JDQ443",
            "Drug: Ribociclib"
          ]
        },
        {
          "label": "JDQ443+cetuximab",
          "type": "EXPERIMENTAL",
          "description": "JDQ443 in combination with cetuximab",
          "interventionNames": [
            "Drug: JDQ443",
            "Biological: cetuximab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "JDQ443",
          "description": "KRAS G12C inhibitor, oral",
          "armGroupLabels": [
            "JDQ443+cetuximab",
            "JDQ443+ribociclib",
            "JDQ443+trametinib"
          ]
        },
        {
          "type": "DRUG",
          "name": "trametinib",
          "description": "MEK inhibitor, oral",
          "armGroupLabels": [
            "JDQ443+trametinib"
          ],
          "otherNames": [
            "TMT212"
          ]
        },
        {
          "type": "DRUG",
          "name": "Ribociclib",
          "description": "CDK4/6 inhibitor, oral",
          "armGroupLabels": [
            "JDQ443+ribociclib"
          ],
          "otherNames": [
            "LEE011"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "cetuximab",
          "description": "EGFR inhibitor, intravenous",
          "armGroupLabels": [
            "JDQ443+cetuximab"
          ]
        }
      ],
      "primaryOutcomes": [
        {
          "measure": "Dose escalation: Incidence and severity of dose limiting toxicities (DLTs) of each combination treatment.",
          "description": "A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value that is not primarily related to disease, disease progression, intercurrent illness/injury, or concomitant medications that occurs within the first 28 days of study treatment and meets a defined criteria.",
          "timeFrame": "28 days"
        },
        {
          "measure": "Dose escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment",
          "description": "All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs).",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose escalation: Frequency of dose interruptions and reductions, by treatment",
          "description": "The number of patients with dose adjustments (reductions and interruptions) will be summarized by treatment group.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose Escalation: Dose intensity by treatment",
          "description": "Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of response.",
          "timeFrame": "24 months"
        },
        {
          "measure": "PhaseII: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1",
          "description": "ORR is the proportion of patients with a best overall response (BOR) of Complete Response (CR) or Partial Response (PR).",
          "timeFrame": "24 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Dose escalation and Phase II: ORR by local review per RECIST 1.1",
          "description": "ORR is the proportion of patients with a BOR of CR or PR.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose escalation and Phase II: Disease Control Rate (DCR) by local review per RECIST 1.1",
          "description": "DCR is the proportion of patients with a BOR of CR or PR or Stable Disease (SD). The objective of this endpoint is to summarize patients with signs of \"activity\" defined as either shrinkage of tumor (regardless of duration) or slowing down of tumor growth.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose escalation and Phase II: Duration of Response (DoR) by local review per RECIST 1.1",
          "description": "Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose escalation and Phase II: Progression-Free Survival (PFS) by local review per RECIST 1.1",
          "description": "PFS is defined as the time from the date of start of treatment to the date of the first documented progression, or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Phase II: DCR by BIRC per RECIST 1.1",
          "description": "DCR is the proportion of patients with a BOR of CR or PR or SD. The objective of this endpoint is to summarize patients with signs of \"activity\" defined as either shrinkage of tumor (regardless of duration) or slowing down of tumor growth.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Phase II: DoR by BIRC per RECIST 1.1",
          "description": "Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due any cause.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Phase II: PFS by BIRC per RECIST 1.1",
          "description": "PFS is defined as the time from the date of start of treatment to the date of the first documented progression, or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Phase II: Overall survival (OS)",
          "description": "OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Dose escalation and Phase II: PK parameters - Maximum Concentration (Cmax), as applicable per arm",
          "description": "The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)",
          "timeFrame": "5 months"
        },
        {
          "measure": "Dose escalation and Phase II: PK parameters - Minimum Concentration (Cmin), as applicable per arm",
          "description": "Observed concentration at the end of a dosing interval (taken directly before next administration)",
          "timeFrame": "5 months"
        },
        {
          "measure": "Dose escalation: Time to achieve Cmax - Tmax, as applicable per arm",
          "description": "The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)",
          "timeFrame": "5 months"
        },
        {
          "measure": "Dose escalation and Phase II: Plasma or serum concentration vs time profiles - AUCtau, as applicable per arm",
          "description": "The Area under curve calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)",
          "timeFrame": "5 months"
        },
        {
          "measure": "Dose escalation and Phase II: Plasma or serum concentration vs time profiles - AUCinf, as applicable per arm",
          "description": "The AUC from time zero to infinity (mass x time x volume-1)",
          "timeFrame": "5 months"
        },
        {
          "measure": "Phase II: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by treatment",
          "description": "All information obtained on AE will be displayed by treatment group. Summary tables will include only AEs that started/worsened during the cycles of treatment (treatment-emergent AEs).",
          "timeFrame": "24 months"
        },
        {
          "measure": "Phase II: Frequency of dose interruptions and reductions, by treatment",
          "description": "The number of patients with dose adjustments (reductions and interruptions) will be summarized by treatment group.",
          "timeFrame": "24 months"
        },
        {
          "measure": "Phase II: Dose intensity by treatment",
          "description": "Dose intensity is defined as the ratio of actual cumulative dose received and actual duration of response.",
          "timeFrame": "24 months"
        }
      ],
      "eligibilityCriteria": "Inclusion Criteria:\n\nDose Escalation:\n\n- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.\n\nPhase II:\n\n* Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy\n* Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy.\n\nAll patients:\n\n* ECOG performance status of 0 or 1.\n* Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines.\n\nExclusion Criteria:\n\n* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations\n* Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.\n* Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease\n* Clinically significant cardiac disease or risk factors at screening\n* Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply",
      "nctId": "NCT05358249",
      "overallStatus": "RECRUITING",
      "keywords": [
        "KRAS G12C",
        "targeted therapy",
        "NSCLC",
        "CRC",
        "advanced solid tumors",
        "JDQ443",
        "trametinib",
        "ribociclib",
        "cetuximab"
      ],
      "locations": [
        {
          "facility": "Massachusetts General Hospital .",
          "status": "RECRUITING",
          "city": "Boston",
          "state": "Massachusetts",
          "zip": "02114",
          "country": "United States",
          "contacts": [
            {
              "name": "Aaron Paul Doss",
              "role": "CONTACT",
              "email": "APAULDOSS@mgh.harvard.edu"
            },
            {
              "name": "Rebecca Heist",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 42.35843,
            "lon": -71.05977
          }
        },
        {
          "facility": "Dana Farber Cancer Institute Dept.of DFCI",
          "status": "RECRUITING",
          "city": "Boston",
          "state": "Massachusetts",
          "zip": "02215",
          "country": "United States",
          "contacts": [
            {
              "name": "Brian Schwalm",
              "role": "CONTACT",
              "email": "brian_schwalm@dfci.harvard.edu"
            },
            {
              "name": "Jia Luo",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 42.35843,
            "lon": -71.05977
          }
        },
        {
          "facility": "NYU School of Medicine Langone Health",
          "status": "RECRUITING",
          "city": "New York",
          "state": "New York",
          "zip": "10015",
          "country": "United States",
          "contacts": [
            {
              "name": "Sasha Richardson",
              "role": "CONTACT",
              "phone": "212-731-5662",
              "email": "sasha.richardson@nyulangone.org"
            },
            {
              "name": "Janice Mehnert",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Leuven",
          "zip": "3000",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.87959,
            "lon": 4.70093
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Bordeaux",
          "zip": "33076",
          "country": "France",
          "geoPoint": {
            "lat": 44.84044,
            "lon": -0.5805
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Lyon",
          "zip": "69373",
          "country": "France",
          "geoPoint": {
            "lat": 45.74848,
            "lon": 4.84669
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Freiburg",
          "zip": "79106",
          "country": "Germany",
          "geoPoint": {
            "lat": 47.9959,
            "lon": 7.85222
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Ulm",
          "zip": "89081",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.39841,
            "lon": 9.99155
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Milano",
          "state": "MI",
          "zip": "20162",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "03080",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Singapore",
          "zip": "168583",
          "country": "Singapore",
          "geoPoint": {
            "lat": 1.28967,
            "lon": 103.85007
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Barcelona",
          "state": "Catalunya",
          "zip": "08036",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28034",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Novartis Investigative Site",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28050",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        }
      ],
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\nDose Escalation:\n\n- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.\n\nPhase II:\n\n* Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy\n* Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy.\n\nAll patients:\n\n* ECOG performance status of 0 or 1.\n* Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines.\n\nExclusion Criteria:\n\n* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations\n* Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.\n* Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease\n* Clinically significant cardiac disease or risk factors at screening\n* Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": [
          "ADULT",
          "OLDER_ADULT"
        ]
      },
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ]
    },
    "structured_criteria": {
      "inclusion": {
        "Inclusion Criteria:": [
          "Patients who meet all of the following criteria are eligible for trial participation: ",
          [
            [
              "Dose Escalation:",
              "- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy."
            ],
            [
              "Phase II:",
              "* Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy",
              "* Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy."
            ],
            [
              "All patients:",
              "* ECOG performance status of 0 or 1.",
              "* Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines."
            ]
          ]
        ]
      },
      "exclusion": {
        "Exclusion Criteria:": [
          "Patients who meet any of the following criteria are not eligible for trial participation: ",
          [
            "* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations",
            "* Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.",
            "* Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease",
            "* Clinically significant cardiac disease or risk factors at screening",
            "* Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply"
          ]
        ]
      }
    },
    "results_inclusion": [
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "Dose Escalation:",
          "- Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy."
        ],
        {
          "reasoning": "produce the criteria_decision. We need to evaluate each inclusion criterion based on the patient information provided. \n\n### Step-by-Step Reasoning:\n\n1. **Global Condition:**\n   - The global condition is \"Dose Escalation\".\n   - This does not provide any specific inclusion criteria by itself, so we will focus on the subcriteria.\n\n2. **Subcriteria:**\n   - **Criterion 1:** \"Patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care therapy or are ineligible to receive such therapy.\"\n     - **Patient Information:**\n       - Diagnosis: Metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC).\n       - The patient has received standard of care therapy (chemotherapy and immunotherapy).\n     - **Decision:** True, because the patient has a KRAS G12C mutant solid tumor and has received standard of care therapy.\n\n### Criteria Decision:\n\n```json\n{\n  \"criteria_result\": {\n    \"explanation\": [\n      \"The global condition 'Dose Escalation' does not provide specific inclusion criteria by itself.\",\n      \"The patient has a KRAS G12C mutant solid tumor and has received standard of care therapy, meeting the inclusion criterion.\"\n    ],\n    \"criteria_decision\": [true, true]\n  },\n  \"global_result\": true\n}\n```\n\n### Explanation:\n- The global condition \"Dose Escalation\" is not a specific criterion but a header for the following subcriteria.\n- The patient meets the subcriterion of having a KRAS G12C mutant solid tumor and having received standard of care therapy.\n- Therefore, the patient is eligible for the trial based on the provided inclusion criteria.",
          "criteria_decision": {
            "criteria_result": {
              "explanation": [
                "The global condition 'Dose Escalation' does not provide specific inclusion criteria by itself.",
                "The patient has a KRAS G12C mutant solid tumor and has received standard of care therapy, meeting the inclusion criterion."
              ],
              "criteria_decision": [
                "?",
                true
              ]
            },
            "global_result": true
          }
        }
      ],
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "Phase II:",
          "* Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy",
          "* Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy."
        ],
        {
          "reasoning": "Let's think step by step in order to produce the criteria decision. We will evaluate each inclusion criterion based on the patient information provided.\n\n### Step-by-Step Reasoning:\n\n1. **Global Condition: Phase II**\n   - This is a general phase designation and does not affect eligibility directly. We will focus on the specific subcriteria.\n\n2. **Criterion 1: Patients with advanced (metastatic or unresectable) KRAS G12C mutant non-small cell lung cancer who have received platinum-based chemotherapy regimen and immune checkpoint inhibitor therapy, unless patient was ineligible to receive such therapy**\n   - The patient has metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC).\n   - The patient has received a platinum-based chemotherapy regimen (Cisplatin and Pemetrexed).\n   - The patient has received immune checkpoint inhibitor therapy (Pembrolizumab).\n   - Therefore, the patient meets this criterion.\n\n3. **Criterion 2: Patients with advanced (metastatic or unresectable) KRAS G12C mutant colorectal cancer who have received fluropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, unless patient was ineligible to such therapy**\n   - The patient has NSCLC, not colorectal cancer.\n   - Therefore, this criterion is not applicable to the patient.\n\n### Criteria Decision:\n\nBased on the above reasoning, we can summarize the decisions for each criterion and the global result.\n\n```json\n{\n  \"criteria_result\": {\n    \"explanation\": [\n      \"This is a general phase designation and does not affect eligibility directly.\",\n      \"The patient has metastatic KRAS G12C mutant non-small cell lung cancer and has received both platinum-based chemotherapy and immune checkpoint inhibitor therapy.\",\n      \"The patient has NSCLC, not colorectal cancer, so this criterion is not applicable.\"\n    ],\n    \"criteria_decision\": [\n      \"?\",\n      true,\n      false\n    ]\n  },\n  \"global_result\": true\n}\n```\n\n### Explanation:\n\n- **Criterion 1**: The global condition \"Phase II\" is a general designation and does not affect eligibility directly, so we mark it as \"?\".\n- **Criterion 2**: The patient meets the criterion for advanced KRAS G12C mutant NSCLC with the required treatments, so we mark it as `true`.\n- **Criterion 3**: The patient does not have colorectal cancer, so this criterion is not applicable, and we mark it as `false`.\n\nThe global result is `true` because the patient meets the relevant criterion for the trial.",
          "criteria_decision": {
            "criteria_result": {
              "explanation": [
                "This is a general phase designation and does not affect eligibility directly.",
                "The patient has metastatic KRAS G12C mutant non-small cell lung cancer and has received both platinum-based chemotherapy and immune checkpoint inhibitor therapy.",
                "The patient has NSCLC, not colorectal cancer, so this criterion is not applicable."
              ],
              "criteria_decision": [
                "?",
                true,
                false
              ]
            },
            "global_result": true
          }
        }
      ],
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "All patients:",
          "* ECOG performance status of 0 or 1.",
          "* Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines."
        ],
        {
          "reasoning": "```json\n{\n  \"criteria_result\": {\n    \"explanation\": [\n      \"The patient has an ECOG performance status of 1, which meets the criterion.\",\n      \"The patient has a site of disease amenable to biopsy (lung tumor), and there is no indication that he is not a candidate for tumor biopsy according to the treating institution's guidelines.\",\n      \"The global condition 'All patients' is met as the patient satisfies all the subcriteria.\"\n    ],\n    \"criteria_decision\": [true, true, true]\n  },\n  \"global_result\": true\n}\n```",
          "criteria_decision": {
            "criteria_result": {
              "explanation": [
                "The patient has an ECOG performance status of 1, which meets the criterion.",
                "The patient has a site of disease amenable to biopsy (lung tumor), and there is no indication that he is not a candidate for tumor biopsy according to the treating institution's guidelines.",
                "The global condition 'All patients' is met as the patient satisfies all the subcriteria."
              ],
              "criteria_decision": [
                true,
                true,
                true
              ]
            },
            "global_result": true
          }
        }
      ]
    ],
    "results_exclusion": [
      [
        "Exclusion Criteria:",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations",
          "* Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II.",
          "* Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease",
          "* Clinically significant cardiac disease or risk factors at screening",
          "* Insufficient bone marrow, hepatic or renal function at screening Other protocol-defined inclusion/exclusion criteria may apply"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each exclusion criterion based on the provided patient information.\n\n1. **Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations**:\n   - The patient has a KRAS G12C mutation, which is explicitly mentioned as an exception. Therefore, the patient is eligible.\n   - Decision: **True**\n\n2. **Prior treatment with a KRAS G12C inhibitor is excluded for patients in a subset of groups in Phase II**:\n   - There is no mention of the patient having received a KRAS G12C inhibitor. Therefore, we assume the patient has not received this treatment.\n   - Decision: **True**\n\n3. **Active brain metastases, including symptomatic brain metastases or known leptomeningeal disease**:\n   - The MRI scan of the brain conducted on March 12, 2024, showed no evidence of metastatic disease. Therefore, the patient is eligible.\n   - Decision: **True**\n\n4. **Clinically significant cardiac disease or risk factors at screening**:\n   - The patient has hypertension, which is controlled with medication. There is no mention of any other clinically significant cardiac disease or risk factors.\n   - Decision: **?** (Hypertension is a risk factor, but it is controlled, and there is no further detail on cardiac evaluation)\n\n5. **Insufficient bone marrow, hepatic or renal function at screening**:\n   - The detailed assessment on April 20, 2024, indicates that all routine labs, including liver and renal function tests, are within normal limits. Therefore, the patient is eligible.\n   - Decision: **True**",
          "criteria_decision": {
            "explanation": [
              "The patient has a KRAS G12C mutation, which is explicitly mentioned as an exception. Therefore, the patient is eligible.",
              "There is no mention of the patient having received a KRAS G12C inhibitor. Therefore, we assume the patient has not received this treatment.",
              "The MRI scan of the brain conducted on March 12, 2024, showed no evidence of metastatic disease. Therefore, the patient is eligible.",
              "The patient has hypertension, which is controlled with medication. There is no mention of any other clinically significant cardiac disease or risk factors.",
              "The detailed assessment on April 20, 2024, indicates that all routine labs, including liver and renal function tests, are within normal limits. Therefore, the patient is eligible."
            ],
            "criteria_decision": [
              true,
              true,
              true,
              "?",
              true
            ]
          }
        }
      ]
    ]
  },
  {
    "nctId": "NCT04449874",
    "avg_inclusion_score": 0.8333333333333334,
    "avg_exclusion_score": 1.0,
    "avg_overall_score": 0.9166666666666666,
    "trial": {
      "clean_text": "#briefTitle\nA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation\n\n#officialTitle\nA Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation\n\n#briefSummary\nThis is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.\n\n#conditions\nNon-Small Cell Lung Cancer\nColorectal Cancer\nAdvanced Solid Tumors\n\n",
      "briefTitle": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
      "officialTitle": "A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
      "briefSummary": "This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.",
      "detailedDescription": null,
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Advanced Solid Tumors"
      ],
      "armGroups": [
        {
          "label": "Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)",
          "type": "EXPERIMENTAL",
          "description": "Participants in Stage I will receive GDC-6036 administered orally once daily (PO QD). The dose will be increased in successive cohorts until a study-specific threshold is reached.\n\nParticipants with select solid tumors will be treated with GDC-6036 PO QD in Stage II.",
          "interventionNames": [
            "Drug: GDC-6036"
          ]
        },
        {
          "label": "Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)",
          "type": "EXPERIMENTAL",
          "description": "Participants with non-small cell lung cancer will receive GDC-6036 in combination with atezolizumab.",
          "interventionNames": [
            "Drug: GDC-6036",
            "Drug: Atezolizumab"
          ]
        },
        {
          "label": "Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)",
          "type": "EXPERIMENTAL",
          "description": "Participants with colorectal cancer will receive GDC-6036 in combination with cetuximab.",
          "interventionNames": [
            "Drug: GDC-6036",
            "Drug: Cetuximab"
          ]
        },
        {
          "label": "Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)",
          "type": "EXPERIMENTAL",
          "description": "Participants with solid tumors will receive GDC-6036 in combination with bevacizumab.",
          "interventionNames": [
            "Drug: GDC-6036",
            "Drug: Bevacizumab"
          ]
        },
        {
          "label": "Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)",
          "type": "EXPERIMENTAL",
          "description": "Participants with non-small cell lung cancer will receive GDC-6036 in combination with erlotinib.",
          "interventionNames": [
            "Drug: GDC-6036",
            "Drug: Erlotinib"
          ]
        },
        {
          "label": "Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)",
          "type": "EXPERIMENTAL",
          "description": "Participants with solid tumors will receive GDC-6036 in combination with GDC-1971 PO in Stage I.\n\nParticipants with select solid tumors will be treated with GDC-6036 in combination with GDC-1971 PO in Stage II.",
          "interventionNames": [
            "Drug: GDC-6036",
            "Drug: GDC-1971"
          ]
        },
        {
          "label": "Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)",
          "type": "EXPERIMENTAL",
          "description": "Participants with solid tumors will receive GDC-6036 in combination with inavolisib PO in Stage I.\n\nParticipants with select solid tumors will be treated with GDC-6036 in combination with inavolisib PO in Stage II.",
          "interventionNames": [
            "Drug: GDC-6036",
            "Drug: Inavolisib"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "GDC-6036",
          "description": "The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).",
          "armGroupLabels": [
            "Arm A: Dose-escalation (Stage I), Dose Expansion (Stage II)",
            "Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)",
            "Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)",
            "Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)",
            "Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)",
            "Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)",
            "Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)"
          ]
        },
        {
          "type": "DRUG",
          "name": "Atezolizumab",
          "description": "A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.",
          "armGroupLabels": [
            "Arm B: GDC-6036 + Atezolizumab (Stage I and Stage II)"
          ]
        },
        {
          "type": "DRUG",
          "name": "Cetuximab",
          "description": "Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\\^2) IV infusion followed by 250 mg/m\\^2 IV infusion weekly in 21 day cycles.",
          "armGroupLabels": [
            "Arm C: GDC-6036 + Cetuximab (Stage I and Stage II)"
          ]
        },
        {
          "type": "DRUG",
          "name": "Bevacizumab",
          "description": "A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.",
          "armGroupLabels": [
            "Arm D: GDC-6036 + Bevacizumab (Stage I and Stage II)"
          ]
        },
        {
          "type": "DRUG",
          "name": "Erlotinib",
          "description": "150 mg of erlotinib will be administered PO QD in 21 day cycles.",
          "armGroupLabels": [
            "Arm E: GDC-6036 + Erlotinib (Stage I and Stage II)"
          ]
        },
        {
          "type": "DRUG",
          "name": "GDC-1971",
          "description": "The starting dose of GDC-1971 will be determined from its single-agent dose escalation.",
          "armGroupLabels": [
            "Arm F: GDC-6036 + GDC-1971 (Stage I and Stage II)"
          ]
        },
        {
          "type": "DRUG",
          "name": "Inavolisib",
          "description": "The starting dose of inavolisib will be determined from its single-agent dose escalation.",
          "armGroupLabels": [
            "Arm G: GDC-6036 + Inavolisib (Stage I and Stage II)"
          ]
        }
      ],
      "primaryOutcomes": [
        {
          "measure": "Percentage of Participants With Adverse Events (AEs)",
          "description": "Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)",
          "timeFrame": "From Cycle 1 Day 1 until 28 days after the final dose (or as specified in the protocol). A cycle is 21 days."
        },
        {
          "measure": "Percentage of Participants With Dose-Limiting Toxicities (DLTs)",
          "timeFrame": "From Cycle 1 Day 1 through Day 21. A cycle is 21 days."
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Plasma Concentrations of GDC-6036",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Plasma Concentrations of Erlotinib",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Plasma Concentrations of GDC-1971",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Plasma Concentrations of Inavolisib",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
          "timeFrame": "Every 6 weeks from Cycle 1 Day 1 until study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1",
          "timeFrame": "Every 6 weeks from Cycle 1 Day 1 until study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Progression-free survival (PFS) as determined by the investigator according to RECIST v1.1",
          "timeFrame": "Every 6 weeks from Cycle 1 Day 1 until study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Relationship Between GDC-6036 Exposure (Maximum Plasma Concentration Observed [Cmax])",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Relationship Between GDC-6036 Exposure (Time to Maximum Plasma Concentration [Tmax])",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Relationship Between GDC-6036 Exposure (Half-life [t1/2])",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Relationship Between GDC-6036 Exposure (Area Under the Curve [AUC])",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        },
        {
          "measure": "Relationship Between Tumor Pharmacodynamic Effects of GDC-6036",
          "timeFrame": "Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (within 28 days after the final dose of study drug). A cycle is 21 days."
        }
      ],
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.\n* Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.\n* Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.\n\nExclusion Criteria:\n\n* Active brain metastases.\n* Malabsorption or other condition that interferes with enteral absorption.\n* Clinically significant cardiovascular dysfunction or liver disease.",
      "nctId": "NCT04449874",
      "overallStatus": "RECRUITING",
      "keywords": [
        "KRAS G12C",
        "Non-Small Cell Lung Cancer",
        "Colorectal Cancer",
        "GDC-6036",
        "Metastatic Solid Tumor",
        "Atezolizumab",
        "Bevacizumab",
        "Cetuximab",
        "Erlotinib",
        "Inavolisib",
        "GDC-1971",
        "SHP2"
      ],
      "locations": [
        {
          "facility": "City of Hope Comprehensive Cancer Center",
          "status": "RECRUITING",
          "city": "Duarte",
          "state": "California",
          "zip": "91010",
          "country": "United States",
          "geoPoint": {
            "lat": 34.13945,
            "lon": -117.97729
          }
        },
        {
          "facility": "UCSD Moores Cancer Center",
          "status": "RECRUITING",
          "city": "La Jolla",
          "state": "California",
          "zip": "92093",
          "country": "United States",
          "geoPoint": {
            "lat": 32.84727,
            "lon": -117.2742
          }
        },
        {
          "facility": "Chao Family Comprehensive Cancer Center UCI",
          "status": "RECRUITING",
          "city": "Orange",
          "state": "California",
          "zip": "92868",
          "country": "United States",
          "geoPoint": {
            "lat": 33.78779,
            "lon": -117.85311
          }
        },
        {
          "facility": "Univ of Calif, San Francisco; Breast Cancer Center",
          "status": "WITHDRAWN",
          "city": "San Francisco",
          "state": "California",
          "zip": "94115",
          "country": "United States",
          "geoPoint": {
            "lat": 37.77493,
            "lon": -122.41942
          }
        },
        {
          "facility": "Yale Cancer Center",
          "status": "RECRUITING",
          "city": "New Haven",
          "state": "Connecticut",
          "zip": "06520",
          "country": "United States",
          "geoPoint": {
            "lat": 41.30815,
            "lon": -72.92816
          }
        },
        {
          "facility": "Florida Cancer Specialists - Sarasota",
          "status": "RECRUITING",
          "city": "Sarasota",
          "state": "Florida",
          "zip": "34232",
          "country": "United States",
          "geoPoint": {
            "lat": 27.33643,
            "lon": -82.53065
          }
        },
        {
          "facility": "Dana Farber Cancer Institute",
          "status": "RECRUITING",
          "city": "Boston",
          "state": "Massachusetts",
          "zip": "02215",
          "country": "United States",
          "geoPoint": {
            "lat": 42.35843,
            "lon": -71.05977
          }
        },
        {
          "facility": "Memorial Sloan Kettering Cancer Center",
          "status": "RECRUITING",
          "city": "New York",
          "state": "New York",
          "zip": "11101",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "University of Oklahoma; Stephenson Oklahoma Canc Ctr",
          "status": "RECRUITING",
          "city": "Oklahoma City",
          "state": "Oklahoma",
          "zip": "73104",
          "country": "United States",
          "geoPoint": {
            "lat": 35.46756,
            "lon": -97.51643
          }
        },
        {
          "facility": "Abramson Cancer Center; Univ of Pennsylvania",
          "status": "RECRUITING",
          "city": "Philadelphia",
          "state": "Pennsylvania",
          "zip": "19104",
          "country": "United States",
          "geoPoint": {
            "lat": 39.95233,
            "lon": -75.16379
          }
        },
        {
          "facility": "UPMC - Hillman Cancer Center",
          "status": "RECRUITING",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15232",
          "country": "United States",
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        },
        {
          "facility": "St Vincent's Hospital Sydney",
          "status": "RECRUITING",
          "city": "Darlinghurst",
          "state": "New South Wales",
          "zip": "2010",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.87939,
            "lon": 151.21925
          }
        },
        {
          "facility": "Slade Health Inward goods",
          "status": "RECRUITING",
          "city": "Mount Kuring-gai",
          "state": "New South Wales",
          "zip": "2080",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.64197,
            "lon": 151.12865
          }
        },
        {
          "facility": "Alfred Health",
          "status": "RECRUITING",
          "city": "Melbourne",
          "state": "Victoria",
          "zip": "3004",
          "country": "Australia",
          "geoPoint": {
            "lat": -37.814,
            "lon": 144.96332
          }
        },
        {
          "facility": "Peter MacCallum Cancer Center",
          "status": "RECRUITING",
          "city": "North Melbourne",
          "state": "Victoria",
          "zip": "3051",
          "country": "Australia",
          "geoPoint": {
            "lat": -37.80132,
            "lon": 144.95822
          }
        },
        {
          "facility": "Linear Clinical Research Limited",
          "status": "RECRUITING",
          "city": "Nedlands",
          "state": "Western Australia",
          "zip": "6009",
          "country": "Australia",
          "geoPoint": {
            "lat": -31.98184,
            "lon": 115.8073
          }
        },
        {
          "facility": "UZ Antwerpen",
          "status": "RECRUITING",
          "city": "Edegem",
          "zip": "2650",
          "country": "Belgium",
          "geoPoint": {
            "lat": 51.15662,
            "lon": 4.44504
          }
        },
        {
          "facility": "CHU de Li\u00e8ge",
          "status": "RECRUITING",
          "city": "Li\u00e8ge",
          "zip": "4000",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.63373,
            "lon": 5.56749
          }
        },
        {
          "facility": "AZ St Maarten Campus Leopoldstr",
          "status": "ACTIVE_NOT_RECRUITING",
          "city": "Mechelen",
          "zip": "2800",
          "country": "Belgium",
          "geoPoint": {
            "lat": 51.02574,
            "lon": 4.47762
          }
        },
        {
          "facility": "Santa Casa de Misericordia de Belo Horizonte - PPDS",
          "status": "RECRUITING",
          "city": "Belo Horizonte",
          "state": "MG",
          "zip": "30150-221",
          "country": "Brazil",
          "geoPoint": {
            "lat": -19.92083,
            "lon": -43.93778
          }
        },
        {
          "facility": "Hospital de Clinicas de Porto Alegre HCPA PPDS",
          "status": "RECRUITING",
          "city": "Porto Alegre",
          "state": "PA",
          "zip": "90035-903",
          "country": "Brazil",
          "geoPoint": {
            "lat": -30.03306,
            "lon": -51.23
          }
        },
        {
          "facility": "Hospital Erasto Gaertner",
          "status": "RECRUITING",
          "city": "Curitiba",
          "state": "PR",
          "zip": "81520-060",
          "country": "Brazil",
          "geoPoint": {
            "lat": -25.42778,
            "lon": -49.27306
          }
        },
        {
          "facility": "Instituto Nacional de C\u00e2ncer",
          "status": "RECRUITING",
          "city": "Rio de Janeiro",
          "state": "RJ",
          "zip": "20230-130",
          "country": "Brazil",
          "geoPoint": {
            "lat": -22.90278,
            "lon": -43.2075
          }
        },
        {
          "facility": "Universidade de Caxias do Sul",
          "status": "RECRUITING",
          "city": "Caxias Do Sul",
          "state": "RS",
          "zip": "95070-561",
          "country": "Brazil",
          "geoPoint": {
            "lat": -29.16806,
            "lon": -51.17944
          }
        },
        {
          "facility": "Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)",
          "status": "RECRUITING",
          "city": "Porto Alegre",
          "state": "RS",
          "zip": "90610-000",
          "country": "Brazil",
          "geoPoint": {
            "lat": -30.03306,
            "lon": -51.23
          }
        },
        {
          "facility": "Hospital de Cancer de Barretos",
          "status": "RECRUITING",
          "city": "Barretos",
          "state": "SP",
          "zip": "14784-400",
          "country": "Brazil",
          "geoPoint": {
            "lat": -20.55722,
            "lon": -48.56778
          }
        },
        {
          "facility": "Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS",
          "status": "RECRUITING",
          "city": "Sao Jose Do Rio Preto",
          "state": "SP",
          "zip": "15090-000",
          "country": "Brazil",
          "geoPoint": {
            "lat": -20.81972,
            "lon": -49.37944
          }
        },
        {
          "facility": "Instituto do Cancer do Estado de Sao Paulo - ICESP",
          "status": "RECRUITING",
          "city": "Sao Paulo",
          "state": "SP",
          "zip": "01246-000",
          "country": "Brazil",
          "geoPoint": {
            "lat": -23.5475,
            "lon": -46.63611
          }
        },
        {
          "facility": "Ottawa Hospital",
          "status": "RECRUITING",
          "city": "Ottawa",
          "state": "Ontario",
          "zip": "K1H 8L6",
          "country": "Canada",
          "geoPoint": {
            "lat": 45.41117,
            "lon": -75.69812
          }
        },
        {
          "facility": "Princess Margaret Cancer Centre",
          "status": "RECRUITING",
          "city": "Toronto",
          "state": "Ontario",
          "zip": "M5G 1Z5",
          "country": "Canada",
          "geoPoint": {
            "lat": 43.70011,
            "lon": -79.4163
          }
        },
        {
          "facility": "Jewish General Hospital; Sir Mortimer B. Davis",
          "status": "RECRUITING",
          "city": "Montreal",
          "state": "Quebec",
          "zip": "H2W 1S6",
          "country": "Canada",
          "geoPoint": {
            "lat": 45.50884,
            "lon": -73.58781
          }
        },
        {
          "facility": "Universit\u00e4tsklinikum \"Carl Gustav Carus\" der Technischen Universit\u00e4t Dresden",
          "status": "WITHDRAWN",
          "city": "Dresden",
          "zip": "01307",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.05089,
            "lon": 13.73832
          }
        },
        {
          "facility": "Semmelweis Egyetem; Belgyogyaszati es Hematologiai Klinika",
          "status": "WITHDRAWN",
          "city": "Budapest",
          "zip": "1088",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.49801,
            "lon": 19.03991
          }
        },
        {
          "facility": "Clinexpert Kft. - Gyongyos",
          "status": "RECRUITING",
          "city": "Gyongyos",
          "zip": "3200",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.78257,
            "lon": 19.928
          }
        },
        {
          "facility": "Rambam Medical Center",
          "status": "RECRUITING",
          "city": "Haifa",
          "zip": "3109601",
          "country": "Israel",
          "geoPoint": {
            "lat": 32.81841,
            "lon": 34.9885
          }
        },
        {
          "facility": "Sheba Medical Center - PPDS",
          "status": "RECRUITING",
          "city": "Ramat Gan",
          "zip": "5266202",
          "country": "Israel",
          "geoPoint": {
            "lat": 32.08227,
            "lon": 34.81065
          }
        },
        {
          "facility": "Tel-Aviv Sourasky Medical Center",
          "status": "RECRUITING",
          "city": "Tel Aviv",
          "zip": "6423906",
          "country": "Israel",
          "geoPoint": {
            "lat": 32.08088,
            "lon": 34.78057
          }
        },
        {
          "facility": "Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS",
          "status": "COMPLETED",
          "city": "Meldola",
          "state": "Emilia-Romagna",
          "zip": "47014",
          "country": "Italy",
          "geoPoint": {
            "lat": 44.12775,
            "lon": 12.0626
          }
        },
        {
          "facility": "Irccs Ospedale San Raffaele;Oncologia Medica",
          "status": "RECRUITING",
          "city": "Milano",
          "state": "Lombardia",
          "zip": "20132",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Asst Grande Ospedale Metropolitano Niguarda",
          "status": "RECRUITING",
          "city": "Milano",
          "state": "Lombardia",
          "zip": "20162",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Istituto Clinico Humanitas",
          "status": "RECRUITING",
          "city": "Rozzano (MI)",
          "state": "Lombardia",
          "zip": "20089",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.38193,
            "lon": 9.1559
          }
        },
        {
          "facility": "Azienda Ospedaliero Universitaria Pisana",
          "status": "RECRUITING",
          "city": "Pisa",
          "state": "Toscana",
          "zip": "56126",
          "country": "Italy",
          "geoPoint": {
            "lat": 43.70853,
            "lon": 10.4036
          }
        },
        {
          "facility": "Aga Khan University Hospital",
          "status": "RECRUITING",
          "city": "Nairobi",
          "zip": "00100",
          "country": "Kenya",
          "geoPoint": {
            "lat": -1.28333,
            "lon": 36.81667
          }
        },
        {
          "facility": "Seoul National University Bundang Hospital",
          "status": "RECRUITING",
          "city": "Seongnam-si",
          "zip": "463-707",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.43861,
            "lon": 127.13778
          }
        },
        {
          "facility": "Seoul National University Hospital",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "03080",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Asan Medical Center - PPDS",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "05505",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Samsung Medical Center - PPDS",
          "status": "RECRUITING",
          "city": "Seoul",
          "zip": "06351",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis",
          "status": "RECRUITING",
          "city": "Amsterdam",
          "zip": "1066 CX",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.37403,
            "lon": 4.88969
          }
        },
        {
          "facility": "Leids Universitair Medisch Centrum",
          "status": "RECRUITING",
          "city": "Leiden",
          "zip": "2333 ZA",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.15833,
            "lon": 4.49306
          }
        },
        {
          "facility": "Maastricht University Medical Center",
          "status": "RECRUITING",
          "city": "Maastricht",
          "zip": "6229 HX",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 50.84833,
            "lon": 5.68889
          }
        },
        {
          "facility": "Universitair Medisch Centrum Utrecht",
          "status": "RECRUITING",
          "city": "Utrecht",
          "zip": "3584 CX",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.09083,
            "lon": 5.12222
          }
        },
        {
          "facility": "Auckland City Hospital, Cancer and Blood Research",
          "status": "RECRUITING",
          "city": "Auckland",
          "zip": "1023",
          "country": "New Zealand",
          "geoPoint": {
            "lat": -36.84853,
            "lon": 174.76349
          }
        },
        {
          "facility": "Auckland City Hospital",
          "status": "RECRUITING",
          "city": "Auckland",
          "zip": "1023",
          "country": "New Zealand",
          "geoPoint": {
            "lat": -36.84853,
            "lon": 174.76349
          }
        },
        {
          "facility": "New Zealand Clinical Research - Christchurch",
          "status": "RECRUITING",
          "city": "Christchurch",
          "zip": "8011",
          "country": "New Zealand",
          "geoPoint": {
            "lat": -43.53333,
            "lon": 172.63333
          }
        },
        {
          "facility": "Haukeland University Hospital; Hospital Pharmacy",
          "status": "RECRUITING",
          "city": "Bergen",
          "zip": "5053",
          "country": "Norway",
          "geoPoint": {
            "lat": 60.39299,
            "lon": 5.32415
          }
        },
        {
          "facility": "Oslo university hospital Radiumhospitalet",
          "status": "RECRUITING",
          "city": "Oslo",
          "zip": "0424",
          "country": "Norway",
          "geoPoint": {
            "lat": 59.91273,
            "lon": 10.74609
          }
        },
        {
          "facility": "Medical University of Gdansk",
          "status": "RECRUITING",
          "city": "Gdansk",
          "zip": "80-952",
          "country": "Poland",
          "geoPoint": {
            "lat": 54.35205,
            "lon": 18.64637
          }
        },
        {
          "facility": "Biokinetica, Przychodnia Jozefow",
          "status": "RECRUITING",
          "city": "Jozefow",
          "zip": "05-410",
          "country": "Poland",
          "geoPoint": {
            "lat": 52.13707,
            "lon": 21.23589
          }
        },
        {
          "facility": "Uniwersytecki Szpital Kliniczny w Poznaniu",
          "status": "RECRUITING",
          "city": "Pozna?",
          "zip": "60-780",
          "country": "Poland",
          "geoPoint": {
            "lat": 51.84442,
            "lon": 14.61868
          }
        },
        {
          "facility": "Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic",
          "status": "WITHDRAWN",
          "city": "Kazan",
          "state": "Tatarstan",
          "zip": "420029",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 55.78874,
            "lon": 49.12214
          }
        },
        {
          "facility": "Hospital Universitari Vall d'Hebron",
          "status": "RECRUITING",
          "city": "Barcelona",
          "zip": "08035",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "START Madrid-FJD, Hospital Fundacion Jimenez Diaz",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28040",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Hospital Universitario 12 de Octubre",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28041",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Hospital Universitario HM Sanchinarro-CIOCC",
          "status": "RECRUITING",
          "city": "Madrid",
          "zip": "28050",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Hospital Clinico Universitario Virgen de la Victoria",
          "status": "RECRUITING",
          "city": "Malaga",
          "zip": "29010",
          "country": "Spain",
          "geoPoint": {
            "lat": 36.72016,
            "lon": -4.42034
          }
        },
        {
          "facility": "Hospital Universitario Virgen del Roc\u00edo",
          "status": "RECRUITING",
          "city": "Sevilla",
          "zip": "41013",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.38283,
            "lon": -5.97317
          }
        },
        {
          "facility": "Hospital Clinico Universitario de Valencia",
          "status": "RECRUITING",
          "city": "Valencia",
          "zip": "46010",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.46975,
            "lon": -0.37739
          }
        },
        {
          "facility": "Universitaetsspital Basel; Onkologie",
          "status": "WITHDRAWN",
          "city": "Basel",
          "zip": "4031",
          "country": "Switzerland",
          "geoPoint": {
            "lat": 47.55839,
            "lon": 7.57327
          }
        },
        {
          "facility": "Inselspital",
          "status": "RECRUITING",
          "city": "Bern",
          "zip": "3010",
          "country": "Switzerland",
          "geoPoint": {
            "lat": 46.94809,
            "lon": 7.44744
          }
        },
        {
          "facility": "H\u00f4pitaux Universitaires de Gen\u00e8ve",
          "status": "RECRUITING",
          "city": "Gen\u00e8ve",
          "zip": "1211",
          "country": "Switzerland",
          "geoPoint": {
            "lat": 46.20222,
            "lon": 6.14569
          }
        },
        {
          "facility": "Unversit\u00e4tsspital Z\u00fcrich",
          "status": "WITHDRAWN",
          "city": "Z\u00fcrich",
          "zip": "8091",
          "country": "Switzerland",
          "geoPoint": {
            "lat": 47.36667,
            "lon": 8.54999
          }
        },
        {
          "facility": "Queen Elizabeth Hospital",
          "status": "RECRUITING",
          "city": "Birmingham",
          "zip": "B15 2TH",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 52.48142,
            "lon": -1.89983
          }
        },
        {
          "facility": "Velindre Cancer Centre",
          "status": "RECRUITING",
          "city": "Cardiff",
          "zip": "CF14 2TL",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.48,
            "lon": -3.18
          }
        },
        {
          "facility": "University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility",
          "status": "RECRUITING",
          "city": "London",
          "zip": "W1T 7HA",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.50853,
            "lon": -0.12574
          }
        },
        {
          "facility": "The Christie NHS Foundation Trust",
          "status": "RECRUITING",
          "city": "Manchester",
          "zip": "M20 4BX",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 53.48095,
            "lon": -2.23743
          }
        }
      ],
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.\n* Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.\n* Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.\n\nExclusion Criteria:\n\n* Active brain metastases.\n* Malabsorption or other condition that interferes with enteral absorption.\n* Clinically significant cardiovascular dysfunction or liver disease.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": [
          "ADULT",
          "OLDER_ADULT"
        ]
      },
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ]
    },
    "structured_criteria": {
      "inclusion": {
        "Inclusion Criteria:": [
          "Patients who meet all of the following criteria are eligible for trial participation: ",
          [
            "* Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.",
            "* Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.",
            "* Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol."
          ]
        ]
      },
      "exclusion": {
        "Exclusion Criteria:": [
          "Patients who meet any of the following criteria are not eligible for trial participation: ",
          [
            "* Active brain metastases.",
            "* Malabsorption or other condition that interferes with enteral absorption.",
            "* Clinically significant cardiovascular dysfunction or liver disease."
          ]
        ]
      }
    },
    "results_inclusion": [
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "* Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.",
          "* Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.",
          "* Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol."
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each criterion based on the provided patient information.\n\n1. **Criterion 1: \u00ab* Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.\u00bb**\n   - The patient has a histologically documented metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.\n   - Decision: True\n\n2. **Criterion 2: \u00ab* Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.\u00bb**\n   - The patient is male, so this criterion does not apply to him.\n   - Decision: True\n\n3. **Criterion 3: \u00ab* Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.\u00bb**\n   - There is no information provided about the patient's agreement to remain abstinent or use a condom, nor about his agreement to refrain from donating sperm.\n   - Decision: ?",
          "criteria_decision": {
            "explanation": [
              "The patient has a histologically documented metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.",
              "The patient is male, so this criterion does not apply to him.",
              "There is no information provided about the patient's agreement to remain abstinent or use a condom, nor about his agreement to refrain from donating sperm."
            ],
            "criteria_decision": [
              true,
              true,
              "?"
            ]
          }
        }
      ]
    ],
    "results_exclusion": [
      [
        "Exclusion Criteria:",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Active brain metastases.",
          "* Malabsorption or other condition that interferes with enteral absorption.",
          "* Clinically significant cardiovascular dysfunction or liver disease."
        ],
        {
          "reasoning": "```json\n{\n  \"explanation\": [\n    \"The patient underwent an MRI scan of the brain on March 12, 2024, which showed no evidence of metastatic disease. Therefore, the patient does not have active brain metastases.\",\n    \"There is no mention of malabsorption or any other condition that interferes with enteral absorption in the patient information. Therefore, we assume the patient does not have such a condition.\",\n    \"The patient has controlled hypertension and no mention of clinically significant cardiovascular dysfunction or liver disease. Therefore, the patient does not have clinically significant cardiovascular dysfunction or liver disease.\"\n  ],\n  \"criteria_decision\": [true, true, true]\n}\n```",
          "criteria_decision": {
            "explanation": [
              "The patient underwent an MRI scan of the brain on March 12, 2024, which showed no evidence of metastatic disease. Therefore, the patient does not have active brain metastases.",
              "There is no mention of malabsorption or any other condition that interferes with enteral absorption in the patient information. Therefore, we assume the patient does not have such a condition.",
              "The patient has controlled hypertension and no mention of clinically significant cardiovascular dysfunction or liver disease. Therefore, the patient does not have clinically significant cardiovascular dysfunction or liver disease."
            ],
            "criteria_decision": [
              true,
              true,
              true
            ]
          }
        }
      ]
    ]
  },
  {
    "nctId": "NCT05054725",
    "avg_inclusion_score": 1.0,
    "avg_exclusion_score": 0.875,
    "avg_overall_score": 0.9,
    "trial": {
      "clean_text": "#briefTitle\nCombination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies\n\n#officialTitle\nA Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies\n\n#briefSummary\nThe purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC\n\n#detailedDescription\nThis is a phase 2 multicenter, open-label study evaluating the efficacy, safety, tolerability, and pharmacokinetics (PK) of RMC-4630 in combination with sotorasib in subjects with KRASG12C mutant NSCLC after failure of prior standard therapies.\n\n#conditions\nNon-Small Cell Lung Cancer\n\n",
      "briefTitle": "Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies",
      "officialTitle": "A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies",
      "briefSummary": "The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC",
      "detailedDescription": "This is a phase 2 multicenter, open-label study evaluating the efficacy, safety, tolerability, and pharmacokinetics (PK) of RMC-4630 in combination with sotorasib in subjects with KRASG12C mutant NSCLC after failure of prior standard therapies.",
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "armGroups": [
        {
          "label": "RMC-4630 and sotorasib, Safety Run-in",
          "type": "EXPERIMENTAL",
          "description": "Safety Run-In:\n\nRMC-4630 and sotorasib",
          "interventionNames": [
            "Drug: RMC-4630",
            "Drug: Sotorasib"
          ]
        },
        {
          "label": "RMC-4630 and sotorasib, Expansion",
          "type": "EXPERIMENTAL",
          "description": "Dose Expansion:\n\nRMC-4630 and sotorasib",
          "interventionNames": [
            "Drug: RMC-4630",
            "Drug: Sotorasib"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "RMC-4630",
          "description": "RMC-4630 administered orally as a capsule",
          "armGroupLabels": [
            "RMC-4630 and sotorasib, Expansion",
            "RMC-4630 and sotorasib, Safety Run-in"
          ],
          "otherNames": [
            "SAR442720"
          ]
        },
        {
          "type": "DRUG",
          "name": "Sotorasib",
          "description": "Sotorasib administered orally as a tablet",
          "armGroupLabels": [
            "RMC-4630 and sotorasib, Expansion",
            "RMC-4630 and sotorasib, Safety Run-in"
          ],
          "otherNames": [
            "AMG 510",
            "Lumakras"
          ]
        }
      ],
      "primaryOutcomes": [
        {
          "measure": "Objective response rate (ORR)",
          "description": "ORR as assessed per RECIST v1.1",
          "timeFrame": "approximately 12 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Adverse Events",
          "description": "Number of Participants with Adverse Events",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Serious Adverse Events",
          "description": "Number of Participants with Serious Adverse Events",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Vital signs",
          "description": "Number of subjects with clinically significant changes in vital signs",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Clinical laboratory test values",
          "description": "Number of subjects with clinically significant changes in clinical laboratory test values",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "ECGs Measurements",
          "description": "Number of subjects with clinically significant changes in ECGs Measurements",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Concentration of RMC-4630",
          "description": "Trough Concentration of RMC-4630",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Concentration of sotorasib",
          "description": "Trough Concentration of sotorasib",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Duration of response (DOR)",
          "description": "DOR as assessed by RECIST v1.1",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Disease Control Rate (DCR)",
          "description": "DCR as assessed by RECIST v1.1",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Progression-free survival (PFS)",
          "description": "PFS as assessed by RECIST v1.1",
          "timeFrame": "approximately 12 months"
        },
        {
          "measure": "Overall survival (OS)",
          "description": "Overall survival (OS)",
          "timeFrame": "approximately 12 months"
        }
      ],
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject must be \u226518 years of age.\n* Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)\n\nExclusion Criteria\n\n* Primary central nervous system (CNS) tumors\n* Known or suspected leptomeningeal or brain metastases or spinal cord compression\n* Clinically significant cardiac disease\n* Known impairment of GI function that would alter the absorption\n* Active autoimmune disease requiring systemic treatment within past 2 years\n* History of severe allergic reactions to any of the study intervention components\n* Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.\n* Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor",
      "nctId": "NCT05054725",
      "overallStatus": "ACTIVE_NOT_RECRUITING",
      "keywords": [
        "SHP2",
        "NSCLC",
        "KRAS G12C",
        "BRAF Class 1/2/unclassified",
        "KRAS amplification",
        "KRAS mutation",
        "STK11/LKB1",
        "KEAP1",
        "PIK3CA",
        "ATRX",
        "BRCA2",
        "carcinoma, non-small lung cancer",
        "bronchial neoplasms",
        "lung neoplasms",
        "respiratory tract neoplasms",
        "neoplasms by site",
        "neoplasms",
        "lung diseases",
        "respiratory tract diseases"
      ],
      "locations": [
        {
          "facility": "Florida Cancer Specialists",
          "city": "Fort Myers",
          "state": "Florida",
          "zip": "33901",
          "country": "United States",
          "geoPoint": {
            "lat": 26.62168,
            "lon": -81.84059
          }
        },
        {
          "facility": "BRCR Medical Center Inc.",
          "city": "Plantation",
          "state": "Florida",
          "zip": "33322",
          "country": "United States",
          "geoPoint": {
            "lat": 26.13421,
            "lon": -80.23184
          }
        },
        {
          "facility": "Cancer Specialists of North Florida",
          "city": "Saint Augustine",
          "state": "Florida",
          "zip": "32086",
          "country": "United States",
          "geoPoint": {
            "lat": 29.89469,
            "lon": -81.31452
          }
        },
        {
          "facility": "GenHarp Clinical Solutions",
          "city": "Evergreen Park",
          "state": "Illinois",
          "zip": "60805",
          "country": "United States",
          "geoPoint": {
            "lat": 41.72059,
            "lon": -87.70172
          }
        },
        {
          "facility": "Hematology Oncology Clinic",
          "city": "Baton Rouge",
          "state": "Louisiana",
          "zip": "70809",
          "country": "United States",
          "geoPoint": {
            "lat": 30.45075,
            "lon": -91.15455
          }
        },
        {
          "facility": "New England Cancer Specialists",
          "city": "Scarborough",
          "state": "Maine",
          "zip": "04074",
          "country": "United States",
          "geoPoint": {
            "lat": 43.57814,
            "lon": -70.32172
          }
        },
        {
          "facility": "American Oncology Partners of Maryland, PA",
          "city": "Bethesda",
          "state": "Maryland",
          "zip": "20817",
          "country": "United States",
          "geoPoint": {
            "lat": 38.98067,
            "lon": -77.10026
          }
        },
        {
          "facility": "Maryland Oncology Hematology, P.A.",
          "city": "Columbia",
          "state": "Maryland",
          "zip": "21044",
          "country": "United States",
          "geoPoint": {
            "lat": 39.24038,
            "lon": -76.83942
          }
        },
        {
          "facility": "Minnesota Oncology Hematology, P.A.",
          "city": "Minneapolis",
          "state": "Minnesota",
          "zip": "55404",
          "country": "United States",
          "geoPoint": {
            "lat": 44.97997,
            "lon": -93.26384
          }
        },
        {
          "facility": "Nebraska Cancer Specialists",
          "city": "Omaha",
          "state": "Nebraska",
          "zip": "68130",
          "country": "United States",
          "geoPoint": {
            "lat": 41.25626,
            "lon": -95.94043
          }
        },
        {
          "facility": "Comprehensive Cancer Centers of Nevada",
          "city": "Las Vegas",
          "state": "Nevada",
          "zip": "89169",
          "country": "United States",
          "geoPoint": {
            "lat": 36.17497,
            "lon": -115.13722
          }
        },
        {
          "facility": "New Jersey Center for Cancer Research",
          "city": "Brick",
          "state": "New Jersey",
          "zip": "08724",
          "country": "United States",
          "geoPoint": {
            "lat": 40.05928,
            "lon": -74.13708
          }
        },
        {
          "facility": "University of New Mexico Comprehensive Cancer Center",
          "city": "Albuquerque",
          "state": "New Mexico",
          "zip": "87131",
          "country": "United States",
          "geoPoint": {
            "lat": 35.08449,
            "lon": -106.65114
          }
        },
        {
          "facility": "Roswell Park cancer Institute",
          "city": "Buffalo",
          "state": "New York",
          "zip": "14263",
          "country": "United States",
          "geoPoint": {
            "lat": 42.88645,
            "lon": -78.87837
          }
        },
        {
          "facility": "Clinical Research Alliance, Inc.",
          "city": "New York",
          "state": "New York",
          "zip": "10021",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Zangmeister Cancer Center",
          "city": "Columbus",
          "state": "Ohio",
          "zip": "43219",
          "country": "United States",
          "geoPoint": {
            "lat": 39.96118,
            "lon": -82.99879
          }
        },
        {
          "facility": "Charleston Oncology",
          "city": "Charleston",
          "state": "South Carolina",
          "zip": "29414",
          "country": "United States",
          "geoPoint": {
            "lat": 32.77657,
            "lon": -79.93092
          }
        },
        {
          "facility": "Tennessee Oncology",
          "city": "Chattanooga",
          "state": "Tennessee",
          "zip": "37404",
          "country": "United States",
          "geoPoint": {
            "lat": 35.04563,
            "lon": -85.30968
          }
        },
        {
          "facility": "Sarah Cannon Research Institute",
          "city": "Nashville",
          "state": "Tennessee",
          "zip": "37203",
          "country": "United States",
          "geoPoint": {
            "lat": 36.16589,
            "lon": -86.78444
          }
        },
        {
          "facility": "CHRISTUS St. Michael-Colom and Carney Clinic P.A",
          "city": "Texarkana",
          "state": "Texas",
          "zip": "75503",
          "country": "United States",
          "geoPoint": {
            "lat": 33.42513,
            "lon": -94.04769
          }
        },
        {
          "facility": "Virginia Cancer Specialists",
          "city": "Fairfax",
          "state": "Virginia",
          "zip": "22031",
          "country": "United States",
          "geoPoint": {
            "lat": 38.84622,
            "lon": -77.30637
          }
        },
        {
          "facility": "Virginia Oncology Associates",
          "city": "Norfolk",
          "state": "Virginia",
          "zip": "23502",
          "country": "United States",
          "geoPoint": {
            "lat": 36.84681,
            "lon": -76.28522
          }
        },
        {
          "facility": "Northwest Cancer specialists, P.C.",
          "city": "Vancouver",
          "state": "Washington",
          "zip": "98684",
          "country": "United States",
          "geoPoint": {
            "lat": 45.63873,
            "lon": -122.66149
          }
        },
        {
          "facility": "South West Oncology",
          "city": "Warrnambool",
          "state": "Victoria",
          "zip": "3280",
          "country": "Australia",
          "geoPoint": {
            "lat": -38.38176,
            "lon": 142.48799
          }
        },
        {
          "facility": "Blacktown Hospital",
          "city": "Blacktown",
          "zip": "2148",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.76667,
            "lon": 150.91667
          }
        },
        {
          "facility": "Goulburn Valley Health",
          "city": "Shepparton",
          "zip": "3630",
          "country": "Australia",
          "geoPoint": {
            "lat": -36.38047,
            "lon": 145.39867
          }
        },
        {
          "facility": "Cross Cancer Institute",
          "city": "Edmonton",
          "state": "Alberta",
          "zip": "T6G 1Z2",
          "country": "Canada",
          "geoPoint": {
            "lat": 53.55014,
            "lon": -113.46871
          }
        },
        {
          "facility": "William Osler Health System",
          "city": "Mississauga",
          "state": "Ontario",
          "zip": "L5N 5M8",
          "country": "Canada",
          "geoPoint": {
            "lat": 43.5789,
            "lon": -79.6583
          }
        },
        {
          "facility": "APHM Hopital Nord, Service d'Oncologie Multidisciplinaire et innovations therapeutics",
          "city": "Marseille",
          "zip": "13015",
          "country": "France",
          "geoPoint": {
            "lat": 43.29551,
            "lon": 5.38958
          }
        },
        {
          "facility": "Hospital Larrey Universite Paul Sabatier",
          "city": "Toulouse",
          "zip": "31059",
          "country": "France",
          "geoPoint": {
            "lat": 43.60426,
            "lon": 1.44367
          }
        },
        {
          "facility": "Klinikum Esslingen GmbH",
          "city": "Esslingen",
          "state": "Baden-Wurttemberg",
          "zip": "73730",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.73961,
            "lon": 9.30473
          }
        },
        {
          "facility": "Asklepios Fachkliniken Munchen",
          "city": "Gauting",
          "state": "Bavaria",
          "zip": "82131",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.06919,
            "lon": 11.37703
          }
        },
        {
          "facility": "Lungenklinik Hemer",
          "city": "Hemer",
          "state": "North Rhine- Westphalia",
          "zip": "58675",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.38707,
            "lon": 7.77019
          }
        },
        {
          "facility": "Bethanien Hospital Moers",
          "city": "Moers",
          "state": "North Rhine-Westphalia",
          "zip": "47441",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.45342,
            "lon": 6.6326
          }
        },
        {
          "facility": "Comprehensive Cancer Center Mainfranken, University Wuerzburg",
          "city": "Homburg",
          "state": "Saarland",
          "zip": "66421",
          "country": "Germany",
          "geoPoint": {
            "lat": 49.32637,
            "lon": 7.33867
          }
        },
        {
          "facility": "Lung Cancer Center, University of Saarland",
          "city": "Homburg",
          "state": "Saarland",
          "zip": "66421",
          "country": "Germany",
          "geoPoint": {
            "lat": 49.32637,
            "lon": 7.33867
          }
        },
        {
          "facility": "POIS Sachsen GmbH",
          "city": "Leipzig",
          "state": "Sachsen",
          "zip": "04347",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.33962,
            "lon": 12.37129
          }
        },
        {
          "facility": "Charite Benjamin Franklin Comprehensive Cancer center",
          "city": "Berlin",
          "zip": "12200",
          "country": "Germany",
          "geoPoint": {
            "lat": 52.52437,
            "lon": 13.41053
          }
        },
        {
          "facility": "Evangelische Lung Clinic",
          "city": "Berlin",
          "zip": "13125",
          "country": "Germany",
          "geoPoint": {
            "lat": 52.52437,
            "lon": 13.41053
          }
        },
        {
          "facility": "Hamato-Onkologie Hamburg",
          "city": "Hamburg",
          "zip": "20251",
          "country": "Germany",
          "geoPoint": {
            "lat": 53.57532,
            "lon": 10.01534
          }
        },
        {
          "facility": "Azienda Ospedaliera dei Colli",
          "city": "Napoli",
          "state": "Campania",
          "zip": "80131",
          "country": "Italy",
          "geoPoint": {
            "lat": 40.85216,
            "lon": 14.26811
          }
        },
        {
          "facility": "Azienda Sanitaria Ospedaliera S Luigi Gonzaga",
          "city": "Orbassano",
          "state": "Piedmont",
          "zip": "10043",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.00547,
            "lon": 7.53813
          }
        },
        {
          "facility": "Istituto Europeo Di Oncologia",
          "city": "Milano",
          "zip": "20141",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Chungbuk National University Hospital",
          "city": "Cheongju-si",
          "zip": "28644",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 36.63722,
            "lon": 127.48972
          }
        },
        {
          "facility": "Seoul National University Hospital",
          "city": "Seoul",
          "zip": "03080",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Asan Medical Center",
          "city": "Seoul",
          "zip": "05505",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Samsung Medical Center",
          "city": "Seoul",
          "zip": "06351",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Hospital Universitario Virgen Macarena",
          "city": "Sevilla",
          "state": "Andalucia",
          "zip": "41009",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.38283,
            "lon": -5.97317
          }
        },
        {
          "facility": "Hospital Clinic de Barcelona",
          "city": "Barcelona",
          "state": "Catalonia",
          "zip": "08036",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Complejo Hospitalario Universitario A Coru\u00f1a",
          "city": "A Coru\u00f1a",
          "state": "Galicia",
          "zip": "15006",
          "country": "Spain",
          "geoPoint": {
            "lat": 43.37135,
            "lon": -8.396
          }
        },
        {
          "facility": "Clinica Universidad de Navarra",
          "city": "Pamplona",
          "state": "Navarra",
          "zip": "31008",
          "country": "Spain",
          "geoPoint": {
            "lat": 42.81687,
            "lon": -1.64323
          }
        },
        {
          "facility": "Clinica Universidad de Navarra",
          "city": "Madrid",
          "zip": "28027",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Hospital Universitario y Politecnico La Fe",
          "city": "Valencia",
          "zip": "46026",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.46975,
            "lon": -0.37739
          }
        },
        {
          "facility": "Kaohsiung Medical University Chung Ho Memorial Hospital",
          "city": "Kaohsiung",
          "zip": "807",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 22.61626,
            "lon": 120.31333
          }
        },
        {
          "facility": "E-DA Hospital",
          "city": "Kaohsiung",
          "zip": "824",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 22.61626,
            "lon": 120.31333
          }
        },
        {
          "facility": "Taichung Veterans General Hospital",
          "city": "Taichung",
          "zip": "40705",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 24.1469,
            "lon": 120.6839
          }
        },
        {
          "facility": "National Cheng Kung University Hospital",
          "city": "Tainan",
          "zip": "704",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 22.99083,
            "lon": 120.21333
          }
        },
        {
          "facility": "National Taiwan University Hospital",
          "city": "Taipei",
          "zip": "10002",
          "country": "Taiwan",
          "geoPoint": {
            "lat": 25.04776,
            "lon": 121.53185
          }
        },
        {
          "facility": "The Christie NHS Foundation Trust",
          "city": "Manchester",
          "state": "Greater Manchester",
          "zip": "M20 4BX",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 53.48095,
            "lon": -2.23743
          }
        },
        {
          "facility": "The Royal Marsden NHS Foundation Trust",
          "city": "Sutton",
          "state": "Surrey",
          "zip": "SM2 5PT",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 51.35,
            "lon": -0.2
          }
        }
      ],
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject must be \u226518 years of age.\n* Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)\n\nExclusion Criteria\n\n* Primary central nervous system (CNS) tumors\n* Known or suspected leptomeningeal or brain metastases or spinal cord compression\n* Clinically significant cardiac disease\n* Known impairment of GI function that would alter the absorption\n* Active autoimmune disease requiring systemic treatment within past 2 years\n* History of severe allergic reactions to any of the study intervention components\n* Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.\n* Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": [
          "ADULT",
          "OLDER_ADULT"
        ]
      },
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ]
    },
    "structured_criteria": {
      "inclusion": {
        "Inclusion Criteria:": [
          "Patients who meet all of the following criteria are eligible for trial participation: ",
          [
            "* Subject must be \u226518 years of age.",
            "* Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)"
          ]
        ]
      },
      "exclusion": {
        "Exclusion Criteria": [
          "Patients who meet any of the following criteria are not eligible for trial participation: ",
          [
            "* Primary central nervous system (CNS) tumors",
            "* Known or suspected leptomeningeal or brain metastases or spinal cord compression",
            "* Clinically significant cardiac disease",
            "* Known impairment of GI function that would alter the absorption",
            "* Active autoimmune disease requiring systemic treatment within past 2 years",
            "* History of severe allergic reactions to any of the study intervention components",
            "* Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.",
            "* Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor"
          ]
        ]
      }
    },
    "results_inclusion": [
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "* Subject must be \u226518 years of age.",
          "* Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed)"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each criterion independently based on the provided patient information.\n\n1. **Criterion 1: Subject must be \u226518 years of age.**\n   - The patient, John Doe, was born on August 18, 1968. As of the current date (April 20, 2024), he is 55 years old.\n   - **Decision: True**\n   - **Explanation: The patient is 55 years old, which is greater than 18 years.**\n\n2. **Criterion 2: Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed).**\n   - The patient has a diagnosis of metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC).\n   - The disease has progressed on prior standard therapies, including chemotherapy and immunotherapy.\n   - The patient has undergone two lines of therapy: chemotherapy (Cisplatin and Pemetrexed) and immunotherapy (Pembrolizumab).\n   - **Decision: True**\n   - **Explanation: The patient has metastatic KRAS G12C NSCLC that has progressed on prior standard therapies, and he has had no more than 3 prior lines of therapy.**",
          "criteria_decision": {
            "explanation": [
              "The patient is 55 years old, which is greater than 18 years.",
              "The patient has metastatic KRAS G12C NSCLC that has progressed on prior standard therapies, and he has had no more than 3 prior lines of therapy."
            ],
            "criteria_decision": [
              true,
              true
            ]
          }
        }
      ]
    ],
    "results_exclusion": [
      [
        "Exclusion Criteria",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Primary central nervous system (CNS) tumors",
          "* Known or suspected leptomeningeal or brain metastases or spinal cord compression",
          "* Clinically significant cardiac disease",
          "* Known impairment of GI function that would alter the absorption",
          "* Active autoimmune disease requiring systemic treatment within past 2 years"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each exclusion criterion based on the provided patient information.\n\n1. **Primary central nervous system (CNS) tumors**:\n   - The patient information does not mention any primary CNS tumors.\n   - Decision: True (The patient is eligible as there is no mention of primary CNS tumors).\n\n2. **Known or suspected leptomeningeal or brain metastases or spinal cord compression**:\n   - The MRI scan of the brain conducted on March 12, 2024, showed no evidence of metastatic disease.\n   - Decision: True (The patient is eligible as there are no known or suspected leptomeningeal or brain metastases or spinal cord compression).\n\n3. **Clinically significant cardiac disease**:\n   - The patient has a thrombus in the left atrium at the transition to the auricle, which could be considered clinically significant cardiac disease.\n   - Decision: False (The patient is not eligible due to the presence of a thrombus in the left atrium).\n\n4. **Known impairment of GI function that would alter the absorption**:\n   - The patient has GERD, but it is managed with Omeprazole and there is no indication that it alters absorption.\n   - Decision: True (The patient is eligible as there is no known impairment of GI function that would alter absorption).\n\n5. **Active autoimmune disease requiring systemic treatment within past 2 years**:\n   - The patient has no mention of any active autoimmune disease requiring systemic treatment within the past 2 years.\n   - Decision: True (The patient is eligible as there is no mention of active autoimmune disease requiring systemic treatment).",
          "criteria_decision": {
            "explanation": [
              "The patient information does not mention any primary CNS tumors.",
              "The MRI scan of the brain conducted on March 12, 2024, showed no evidence of metastatic disease.",
              "The patient has a thrombus in the left atrium at the transition to the auricle, which could be considered clinically significant cardiac disease.",
              "The patient has GERD, but it is managed with Omeprazole and there is no indication that it alters absorption.",
              "The patient has no mention of any active autoimmune disease requiring systemic treatment within the past 2 years."
            ],
            "criteria_decision": [
              true,
              true,
              false,
              true,
              true
            ]
          }
        }
      ],
      [
        "Exclusion Criteria",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* History of severe allergic reactions to any of the study intervention components",
          "* Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.",
          "* Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each exclusion criterion based on the provided patient information.\n\n1. **History of severe allergic reactions to any of the study intervention components**:\n   - The patient information does not mention any history of severe allergic reactions to any components of the study intervention.\n   - Therefore, we assume the patient does not have such a history.\n   - Decision: True\n\n2. **Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment**:\n   - The patient information does not mention any recent major or minor surgical procedures within the specified time frames.\n   - Therefore, we assume the patient has not undergone any such procedures.\n   - Decision: True\n\n3. **Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor**:\n   - The patient information does not mention any prior therapy with KRASG12C inhibitor or SHP2 inhibitor.\n   - Therefore, we assume the patient has not received such therapies.\n   - Decision: True",
          "criteria_decision": {
            "explanation": [
              "The patient information does not mention any history of severe allergic reactions to any components of the study intervention. Therefore, we assume the patient does not have such a history.",
              "The patient information does not mention any recent major or minor surgical procedures within the specified time frames. Therefore, we assume the patient has not undergone any such procedures.",
              "The patient information does not mention any prior therapy with KRASG12C inhibitor or SHP2 inhibitor. Therefore, we assume the patient has not received such therapies."
            ],
            "criteria_decision": [
              true,
              true,
              true
            ]
          }
        }
      ]
    ]
  },
  {
    "nctId": "NCT04933695",
    "avg_inclusion_score": 0.7857142857142857,
    "avg_exclusion_score": 0.8333333333333334,
    "avg_overall_score": 0.8076923076923077,
    "trial": {
      "clean_text": "#briefTitle\nA Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment\n\n#officialTitle\nA Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)\n\n#briefSummary\nThe main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) \\< 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of participants with PD-L1 \\< 1% and in a subgroup of participants with STK11 co-mutation.\n\n#conditions\nNon-small Cell Lung Cancer\n\n",
      "briefTitle": "A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment",
      "officialTitle": "A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)",
      "briefSummary": "The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) \\< 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of participants with PD-L1 \\< 1% and in a subgroup of participants with STK11 co-mutation.",
      "detailedDescription": null,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "armGroups": [
        {
          "label": "Sotorasib: 960 mg Daily",
          "type": "EXPERIMENTAL",
          "description": "Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \\< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 960 mg daily. Participants will be stratified by known presence of STK11 mutation.",
          "interventionNames": [
            "Drug: Sotorasib"
          ]
        },
        {
          "label": "Sotorasib: 240 mg Daily",
          "type": "EXPERIMENTAL",
          "description": "Participants with metastatic non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) p.G12C mutation whose tumors express \\< 1% programmed death-ligand 1 (PD-L1) and/or serine/threonine kinase 11 (STK11) mutation in need of first line treatment will be administered sotorasib 240 mg daily. Participants will be stratified by known presence of STK11 mutation.",
          "interventionNames": [
            "Drug: Sotorasib"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Sotorasib",
          "description": "Oral tablet",
          "armGroupLabels": [
            "Sotorasib: 240 mg Daily",
            "Sotorasib: 960 mg Daily"
          ],
          "otherNames": [
            "AMG 510",
            "LUMYKRAS",
            "LUMAKRAS"
          ]
        }
      ],
      "primaryOutcomes": [
        {
          "measure": "Objective Response Rate (OR)",
          "description": "OR is defined as the total of Complete Response (CR) and Partial Response (PR).",
          "timeFrame": "Up to 6 years"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Disease Control Rate",
          "timeFrame": "Up to 6 years"
        },
        {
          "measure": "Duration of Reponse (DOR)",
          "timeFrame": "Up to 6 years"
        },
        {
          "measure": "Time to Response (TTR)",
          "timeFrame": "Up to 6 years"
        },
        {
          "measure": "Progression-free Survival (PFS)",
          "timeFrame": "Up to 6 years"
        },
        {
          "measure": "Overall Survival (OS)",
          "timeFrame": "Up to 6 years"
        },
        {
          "measure": "Number of Participants with a Treatment-emergent Adverse Event (TEAE)",
          "timeFrame": "Day 1 up to Month 13"
        },
        {
          "measure": "Number of Participants with a Treatment-related Adverse Event",
          "timeFrame": "Day 1 up to Month 13"
        },
        {
          "measure": "Number of Participants with a Clinically Significant Change from Baseline in Vital Signs",
          "timeFrame": "Baseline (Screening; up to 28 days pre-dose) up to Month 13"
        },
        {
          "measure": "Number of Participants with a Clinically Significant Change from Baseline in Electrocardiograms (ECGs)",
          "timeFrame": "Baseline (Screening; up to 28 days pre-dose) up to Month 13"
        },
        {
          "measure": "Number of Participants with a Clinically Significant Change from Baseline in Clinical Laboratory Tests",
          "timeFrame": "Baseline (Screening; up to 28 days pre-dose) up to Month 13"
        },
        {
          "measure": "Maximum Plasma Concentration (Cmax) of Sotorasib",
          "timeFrame": "Day 1 up to Month 3"
        },
        {
          "measure": "Time to Reach Maximum Plasma Concentration (tmax) of Sotorasib",
          "timeFrame": "Day 1 up to Month 3"
        },
        {
          "measure": "Area Under the Plasma Concentration-time Curve (AUC) of Sotorasib",
          "timeFrame": "Day 1 up to Month 3"
        }
      ],
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult (= or \\> 18 years old) with NSCLC\n* Untreated Stage IV metastatic disease. Participants who received adjuvant or neoadjuvant anti-tumor therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic stage IV disease\n* Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)\n* Programmed death-ligand 1 (PD-L1) TPS Score \\< 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation)\n* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n* No active brain metastases\n* Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n\nExclusion Criteria:\n\n* Mixed small-cell lung cancer and NSCLC histology\n* Myocardial Infarction within 6 months of study Day 1\n* Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) or known CYP3A4 sensitive substrates or P-gp substrates\n* Therapeutic or palliative radiation therapy within 2 weeks of study day 1\n* Unable to take oral medication\n* Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans",
      "nctId": "NCT04933695",
      "overallStatus": "ACTIVE_NOT_RECRUITING",
      "keywords": [
        "Non-small cell lung cancer",
        "KRAS p.G12C",
        "Sotorasib",
        "AMG 510"
      ],
      "locations": [
        {
          "facility": "Alabama Oncology",
          "city": "Birmingham",
          "state": "Alabama",
          "zip": "35243",
          "country": "United States",
          "geoPoint": {
            "lat": 33.52066,
            "lon": -86.80249
          }
        },
        {
          "facility": "Arizona Oncology Associates Professional Corporation",
          "city": "Tucson",
          "state": "Arizona",
          "zip": "85711",
          "country": "United States",
          "geoPoint": {
            "lat": 32.22174,
            "lon": -110.92648
          }
        },
        {
          "facility": "City of Hope at Long Beach Elm",
          "city": "Duarte",
          "state": "California",
          "zip": "91010",
          "country": "United States",
          "geoPoint": {
            "lat": 34.13945,
            "lon": -117.97729
          }
        },
        {
          "facility": "City of Hope National Medical Center",
          "city": "Duarte",
          "state": "California",
          "zip": "91010",
          "country": "United States",
          "geoPoint": {
            "lat": 34.13945,
            "lon": -117.97729
          }
        },
        {
          "facility": "Baptist MD Anderson Cancer Center",
          "city": "Jacksonville",
          "state": "Florida",
          "zip": "32207",
          "country": "United States",
          "geoPoint": {
            "lat": 30.33218,
            "lon": -81.65565
          }
        },
        {
          "facility": "Northwest Georgia Oncology Centers PC",
          "city": "Marietta",
          "state": "Georgia",
          "zip": "30060",
          "country": "United States",
          "geoPoint": {
            "lat": 33.9526,
            "lon": -84.54993
          }
        },
        {
          "facility": "Indiana University Melvin and Bren Simon Cancer Center",
          "city": "Indianapolis",
          "state": "Indiana",
          "zip": "46202",
          "country": "United States",
          "geoPoint": {
            "lat": 39.76838,
            "lon": -86.15804
          }
        },
        {
          "facility": "Baptist Health Lexington",
          "city": "Lexington",
          "state": "Kentucky",
          "zip": "40503",
          "country": "United States",
          "geoPoint": {
            "lat": 37.98869,
            "lon": -84.47772
          }
        },
        {
          "facility": "Frederick Memorial Hospital",
          "city": "Frederick",
          "state": "Maryland",
          "zip": "21702",
          "country": "United States",
          "geoPoint": {
            "lat": 39.41427,
            "lon": -77.41054
          }
        },
        {
          "facility": "Englewood Hospital and Medical Center",
          "city": "Englewood",
          "state": "New Jersey",
          "zip": "07631",
          "country": "United States",
          "geoPoint": {
            "lat": 40.89288,
            "lon": -73.97264
          }
        },
        {
          "facility": "Rutgers Cancer Institute of New Jersey",
          "city": "New Brunswick",
          "state": "New Jersey",
          "zip": "08901",
          "country": "United States",
          "geoPoint": {
            "lat": 40.48622,
            "lon": -74.45182
          }
        },
        {
          "facility": "James J Peters VA Medical Center",
          "city": "Bronx",
          "state": "New York",
          "zip": "10468",
          "country": "United States",
          "geoPoint": {
            "lat": 40.84985,
            "lon": -73.86641
          }
        },
        {
          "facility": "Laura and Isaac Perlmutter Cancer Center at New York University Langone",
          "city": "New York",
          "state": "New York",
          "zip": "10016",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Northport Veterans Affairs Medical Center",
          "city": "Northport",
          "state": "New York",
          "zip": "11768",
          "country": "United States",
          "geoPoint": {
            "lat": 40.90093,
            "lon": -73.34317
          }
        },
        {
          "facility": "State University of New York Upstate Medical University",
          "city": "Syracuse",
          "state": "New York",
          "zip": "13210",
          "country": "United States",
          "geoPoint": {
            "lat": 43.04812,
            "lon": -76.14742
          }
        },
        {
          "facility": "Duke University Medical Center, Morris Cancer Clinic",
          "city": "Durham",
          "state": "North Carolina",
          "zip": "27710",
          "country": "United States",
          "geoPoint": {
            "lat": 35.99403,
            "lon": -78.89862
          }
        },
        {
          "facility": "Allegheny Health Network Cancer Institute at Allegheny General Hospital",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15212",
          "country": "United States",
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        },
        {
          "facility": "University of Pittsburgh Medical Center Cancer Pavillion",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15232",
          "country": "United States",
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        },
        {
          "facility": "Medical University of South Carolina, Hollings Cancer Center",
          "city": "Charleston",
          "state": "South Carolina",
          "zip": "29425",
          "country": "United States",
          "geoPoint": {
            "lat": 32.77657,
            "lon": -79.93092
          }
        },
        {
          "facility": "Texas Oncology - Medical City Dallas",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75230-2510",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Texas Oncology - Plano East",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75230-2510",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Texas Oncology-Dallas Presbyterian Hospital",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75231",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Texas Oncology - Flower Mound",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75234",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Texas Oncology - Baylor",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75246",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "Texas Oncology-Denton",
          "city": "Denton",
          "state": "Texas",
          "zip": "76201",
          "country": "United States",
          "geoPoint": {
            "lat": 33.21484,
            "lon": -97.13307
          }
        },
        {
          "facility": "Oncology Consultants PA",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "University of Texas MD Anderson Cancer Center",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "Texas Oncology- Mckinney",
          "city": "McKinney",
          "state": "Texas",
          "zip": "75071",
          "country": "United States",
          "geoPoint": {
            "lat": 33.19762,
            "lon": -96.61527
          }
        },
        {
          "facility": "Texas Oncology - Northeast Texas",
          "city": "Paris",
          "state": "Texas",
          "zip": "75460-5004",
          "country": "United States",
          "geoPoint": {
            "lat": 33.66094,
            "lon": -95.55551
          }
        },
        {
          "facility": "Gundersen Health System",
          "city": "La Crosse",
          "state": "Wisconsin",
          "zip": "54601",
          "country": "United States",
          "geoPoint": {
            "lat": 43.80136,
            "lon": -91.23958
          }
        },
        {
          "facility": "Universite Catholique de Louvain Cliniques Universitaires Saint Luc",
          "city": "Bruxelles",
          "zip": "1200",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.85045,
            "lon": 4.34878
          }
        },
        {
          "facility": "Universitair Ziekenhuis Antwerpen",
          "city": "Edegem",
          "zip": "2650",
          "country": "Belgium",
          "geoPoint": {
            "lat": 51.15662,
            "lon": 4.44504
          }
        },
        {
          "facility": "Jessa Ziekenhuis - Campus Virga Jesse",
          "city": "Hasselt",
          "zip": "3500",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.93106,
            "lon": 5.33781
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire de Liege - Sart Tilman",
          "city": "Liege",
          "zip": "4000",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.63373,
            "lon": 5.56749
          }
        },
        {
          "facility": "Odense Universitetshospital",
          "city": "Odense C",
          "zip": "5000",
          "country": "Denmark",
          "geoPoint": {
            "lat": 55.39594,
            "lon": 10.38831
          }
        },
        {
          "facility": "Institut Sainte Catherine",
          "city": "Avignon cedex 9",
          "zip": "84918",
          "country": "France",
          "geoPoint": {
            "lat": 43.94834,
            "lon": 4.80892
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire R\u00e9gional de Lille - H\u00f4pital Albert Calmette",
          "city": "Lille Cedex",
          "zip": "59037",
          "country": "France",
          "geoPoint": {
            "lat": 50.63297,
            "lon": 3.05858
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire de Limoges - Hopital Dupuytren",
          "city": "Limoges Cedex",
          "zip": "87042",
          "country": "France",
          "geoPoint": {
            "lat": 45.83153,
            "lon": 1.25781
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire de Montpellier - Val d Aurelle",
          "city": "Montpellier Cedex 5",
          "zip": "34298",
          "country": "France",
          "geoPoint": {
            "lat": 43.61092,
            "lon": 3.87723
          }
        },
        {
          "facility": "Hopital Cochin",
          "city": "Paris",
          "zip": "75014",
          "country": "France",
          "geoPoint": {
            "lat": 48.85341,
            "lon": 2.3488
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire de Bordeaux - Hopital Haut Leveque",
          "city": "Pessac Cedex",
          "zip": "33604",
          "country": "France",
          "geoPoint": {
            "lat": 44.81011,
            "lon": -0.64129
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou",
          "city": "Rennes",
          "zip": "35033",
          "country": "France",
          "geoPoint": {
            "lat": 48.11198,
            "lon": -1.67429
          }
        },
        {
          "facility": "Centre Hospitalier de Nantes - H\u00f4pital Nord La\u00ebnnec",
          "city": "Saint Herblain",
          "zip": "44800",
          "country": "France",
          "geoPoint": {
            "lat": 47.21765,
            "lon": -1.64841
          }
        },
        {
          "facility": "H\u00f4pital Sainte Musse",
          "city": "Toulon Cedex",
          "zip": "83056",
          "country": "France",
          "geoPoint": {
            "lat": 43.12442,
            "lon": 5.92836
          }
        },
        {
          "facility": "Centre Hospitalier Universitaire de Toulouse - Hopital Larrey",
          "city": "Toulouse Cedex 9",
          "zip": "31059",
          "country": "France",
          "geoPoint": {
            "lat": 43.60426,
            "lon": 1.44367
          }
        },
        {
          "facility": "Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universit\u00e4t Frankfurt am Main",
          "city": "Frankfurt am Main",
          "zip": "60590",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.11552,
            "lon": 8.68417
          }
        },
        {
          "facility": "Asklepios - Fachkliniken M\u00fcnchen-Gauting",
          "city": "Gauting",
          "zip": "82130",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.06919,
            "lon": 11.37703
          }
        },
        {
          "facility": "Universit\u00e4tsklinikum K\u00f6ln",
          "city": "Koeln",
          "zip": "50937",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.93333,
            "lon": 6.95
          }
        },
        {
          "facility": "Azienda Socio Sanitaria Territoriale di Monza Ospedale San Gerardo",
          "city": "Monza (MB)",
          "zip": "20900",
          "country": "Italy"
        },
        {
          "facility": "Azienda Ospedaliera di Rilievo Nazionale Specialistica dei Colli Monaldi",
          "city": "Napoli",
          "zip": "80131",
          "country": "Italy",
          "geoPoint": {
            "lat": 40.85216,
            "lon": 14.26811
          }
        },
        {
          "facility": "Azienda Ospedaliera Universitaria San Luigi Gonzaga",
          "city": "Orbassano (TO)",
          "zip": "10043",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.00547,
            "lon": 7.53813
          }
        },
        {
          "facility": "Istituti Fisioterapici Ospitalieri Regina Elena San Gallicano",
          "city": "Rome",
          "zip": "00144",
          "country": "Italy",
          "geoPoint": {
            "lat": 41.89193,
            "lon": 12.51133
          }
        },
        {
          "facility": "Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis",
          "city": "Amsterdam",
          "zip": "1066 CX",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.37403,
            "lon": 4.88969
          }
        },
        {
          "facility": "Hospital del Mar",
          "city": "Barcelona",
          "state": "Catalu\u00f1a",
          "zip": "08003",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Hospital de la Santa Creu i Sant Pau",
          "city": "Barcelona",
          "state": "Catalu\u00f1a",
          "zip": "08041",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Hospital Universitari i Politecnic La Fe",
          "city": "Valencia",
          "state": "Comunidad Valenciana",
          "zip": "46026",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.46975,
            "lon": -0.37739
          }
        },
        {
          "facility": "Hospital Clinico Universitario de Santiago",
          "city": "Santiago de Compostela",
          "state": "Galicia",
          "zip": "15706",
          "country": "Spain",
          "geoPoint": {
            "lat": 42.88052,
            "lon": -8.54569
          }
        },
        {
          "facility": "Hospital Universitario Puerta de Hierro Majadahonda",
          "city": "Majadahonda",
          "state": "Madrid",
          "zip": "28222",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.47353,
            "lon": -3.87182
          }
        },
        {
          "facility": "Hospital Universitario La Paz",
          "city": "Madrid",
          "zip": "28046",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Gavle Sjukhus",
          "city": "Gavle",
          "zip": "801 87",
          "country": "Sweden",
          "geoPoint": {
            "lat": 60.67452,
            "lon": 17.14174
          }
        },
        {
          "facility": "Sahlgrenska Universitetssjukhuset",
          "city": "Goteborg",
          "zip": "413 45",
          "country": "Sweden",
          "geoPoint": {
            "lat": 57.70716,
            "lon": 11.96679
          }
        },
        {
          "facility": "Universitetssjukhuset i Linkoping",
          "city": "Linkoping",
          "zip": "581 85",
          "country": "Sweden",
          "geoPoint": {
            "lat": 58.41086,
            "lon": 15.62157
          }
        },
        {
          "facility": "Skanes Universitetssjukhus",
          "city": "Lund",
          "zip": "221 85",
          "country": "Sweden",
          "geoPoint": {
            "lat": 55.70584,
            "lon": 13.19321
          }
        },
        {
          "facility": "Norrlands Universitetssjukhus",
          "city": "Umea",
          "zip": "901 85",
          "country": "Sweden",
          "geoPoint": {
            "lat": 63.82842,
            "lon": 20.25972
          }
        },
        {
          "facility": "Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi",
          "city": "Ankara",
          "zip": "06560",
          "country": "Turkey",
          "geoPoint": {
            "lat": 39.91987,
            "lon": 32.85427
          }
        },
        {
          "facility": "Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi",
          "city": "Edirne",
          "zip": "22030",
          "country": "Turkey",
          "geoPoint": {
            "lat": 41.67719,
            "lon": 26.55597
          }
        },
        {
          "facility": "Koc Universitesi Hastanesi",
          "city": "Istanbul",
          "zip": "34010",
          "country": "Turkey",
          "geoPoint": {
            "lat": 41.01384,
            "lon": 28.94966
          }
        }
      ],
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult (= or \\> 18 years old) with NSCLC\n* Untreated Stage IV metastatic disease. Participants who received adjuvant or neoadjuvant anti-tumor therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic stage IV disease\n* Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)\n* Programmed death-ligand 1 (PD-L1) TPS Score \\< 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation)\n* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n* No active brain metastases\n* Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n\nExclusion Criteria:\n\n* Mixed small-cell lung cancer and NSCLC histology\n* Myocardial Infarction within 6 months of study Day 1\n* Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) or known CYP3A4 sensitive substrates or P-gp substrates\n* Therapeutic or palliative radiation therapy within 2 weeks of study day 1\n* Unable to take oral medication\n* Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": [
          "ADULT",
          "OLDER_ADULT"
        ]
      },
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ]
    },
    "structured_criteria": {
      "inclusion": {
        "Inclusion Criteria:": [
          "Patients who meet all of the following criteria are eligible for trial participation: ",
          [
            "* Adult (= or \\> 18 years old) with NSCLC",
            "* Untreated Stage IV metastatic disease. Participants who received adjuvant or neoadjuvant anti-tumor therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic stage IV disease",
            "* Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)",
            "* Programmed death-ligand 1 (PD-L1) TPS Score \\< 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation)",
            "* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1",
            "* No active brain metastases",
            "* Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria"
          ]
        ]
      },
      "exclusion": {
        "Exclusion Criteria:": [
          "Patients who meet any of the following criteria are not eligible for trial participation: ",
          [
            "* Mixed small-cell lung cancer and NSCLC histology",
            "* Myocardial Infarction within 6 months of study Day 1",
            "* Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) or known CYP3A4 sensitive substrates or P-gp substrates",
            "* Therapeutic or palliative radiation therapy within 2 weeks of study day 1",
            "* Unable to take oral medication",
            "* Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans"
          ]
        ]
      }
    },
    "results_inclusion": [
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "* Adult (= or \\> 18 years old) with NSCLC",
          "* Untreated Stage IV metastatic disease. Participants who received adjuvant or neoadjuvant anti-tumor therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic stage IV disease",
          "* Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)",
          "* Programmed death-ligand 1 (PD-L1) TPS Score \\< 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation)",
          "* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each criterion based on the provided patient information.\n\n1. **Criterion**: \u00ab* Adult (= or \\> 18 years old) with NSCLC\u00bb\n   - **Patient Info**: The patient is 55 years old and has NSCLC.\n   - **Decision**: True\n   - **Explanation**: The patient is an adult (55 years old) and has NSCLC.\n\n2. **Criterion**: \u00ab* Untreated Stage IV metastatic disease. Participants who received adjuvant or neoadjuvant anti-tumor therapy are eligible if the adjuvant/neoadjuvant therapy was completed greater than 12 months prior to the development of metastatic stage IV disease\u00bb\n   - **Patient Info**: The patient has received chemotherapy and immunotherapy for metastatic NSCLC.\n   - **Decision**: False\n   - **Explanation**: The patient has been treated for metastatic NSCLC, which does not meet the criterion of untreated Stage IV metastatic disease.\n\n3. **Criterion**: \u00ab* Pathologically documented metastatic NSCLC with KRAS G12C mutation (local confirmation)\u00bb\n   - **Patient Info**: The patient has metastatic NSCLC with a KRAS G12C mutation.\n   - **Decision**: True\n   - **Explanation**: The patient has a pathologically documented KRAS G12C mutation in metastatic NSCLC.\n\n4. **Criterion**: \u00ab* Programmed death-ligand 1 (PD-L1) TPS Score \\< 1% and/or serine/threonine kinase 11 (STK11) co-mutation (local confirmation)\u00bb\n   - **Patient Info**: The patient has an STK11 p.K83Tfs*13 mutation.\n   - **Decision**: True\n   - **Explanation**: The patient has an STK11 co-mutation, which meets the criterion.\n\n5. **Criterion**: \u00ab* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\u00bb\n   - **Patient Info**: The patient has an ECOG performance status of 1.\n   - **Decision**: True\n   - **Explanation**: The patient has an ECOG score of 1, which meets the criterion.",
          "criteria_decision": {
            "explanation": [
              "The patient is an adult (55 years old) and has NSCLC.",
              "The patient has been treated for metastatic NSCLC, which does not meet the criterion of untreated Stage IV metastatic disease.",
              "The patient has a pathologically documented KRAS G12C mutation in metastatic NSCLC.",
              "The patient has an STK11 co-mutation, which meets the criterion.",
              "The patient has an ECOG score of 1, which meets the criterion."
            ],
            "criteria_decision": [
              true,
              false,
              true,
              true,
              true
            ]
          }
        }
      ],
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "* No active brain metastases",
          "* Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each inclusion criterion based on the provided patient information.\n\n1. **No active brain metastases**:\n   - The patient information states that an MRI scan of the brain was conducted on March 12, 2024, and there was no evidence of metastatic disease in the brain. Therefore, the patient meets this criterion.\n   - Decision: **True**\n\n2. **Measurable disease per investigator interpretation using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria**:\n   - The patient has a diagnosis of metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC) with measurable disease progression noted in follow-up CT scans. However, the specific details regarding the measurement of the disease per RECIST 1.1 criteria are not explicitly mentioned in the patient information.\n   - Decision: **?**",
          "criteria_decision": {
            "explanation": [
              "The patient has no active brain metastases as confirmed by the MRI scan conducted on March 12, 2024.",
              "The patient has measurable disease, but the specific details regarding the measurement per RECIST 1.1 criteria are not provided."
            ],
            "criteria_decision": [
              true,
              "?"
            ]
          }
        }
      ]
    ],
    "results_exclusion": [
      [
        "Exclusion Criteria:",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Mixed small-cell lung cancer and NSCLC histology",
          "* Myocardial Infarction within 6 months of study Day 1",
          "* Use of proton-pump inhibitors (PPIs), histamine (H2) receptor antagonists (H2RA), strong inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) or known CYP3A4 sensitive substrates or P-gp substrates",
          "* Therapeutic or palliative radiation therapy within 2 weeks of study day 1",
          "* Unable to take oral medication"
        ],
        {
          "reasoning": "```json\n{\n  \"explanation\": [\n    \"The patient has a diagnosis of non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. There is no mention of mixed small-cell lung cancer and NSCLC histology. Therefore, the patient is eligible for this criterion.\",\n    \"There is no mention of a myocardial infarction in the patient information. Therefore, the patient is eligible for this criterion.\",\n    \"The patient is taking Omeprazole, which is a proton-pump inhibitor (PPI). Therefore, the patient is not eligible for this criterion.\",\n    \"There is no mention of the patient receiving therapeutic or palliative radiation therapy within 2 weeks of study day 1. Therefore, the patient is eligible for this criterion.\",\n    \"There is no mention of the patient being unable to take oral medication. Therefore, the patient is eligible for this criterion.\"\n  ],\n  \"criteria_decision\": [true, true, false, true, true]\n}\n```",
          "criteria_decision": {
            "explanation": [
              "The patient has a diagnosis of non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. There is no mention of mixed small-cell lung cancer and NSCLC histology. Therefore, the patient is eligible for this criterion.",
              "There is no mention of a myocardial infarction in the patient information. Therefore, the patient is eligible for this criterion.",
              "The patient is taking Omeprazole, which is a proton-pump inhibitor (PPI). Therefore, the patient is not eligible for this criterion.",
              "There is no mention of the patient receiving therapeutic or palliative radiation therapy within 2 weeks of study day 1. Therefore, the patient is eligible for this criterion.",
              "There is no mention of the patient being unable to take oral medication. Therefore, the patient is eligible for this criterion."
            ],
            "criteria_decision": [
              true,
              true,
              false,
              true,
              true
            ]
          }
        }
      ],
      [
        "Exclusion Criteria:",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Unable to receive both iodinated contrast for computed tomography (CT) scans and gadolinium contrast for magnetic resonance imagine (MRI) scans"
        ],
        {
          "reasoning": "```json\n{\n    \"explanation\": [\n        \"The exclusion criterion states that the patient must be unable to receive both iodinated contrast for CT scans and gadolinium contrast for MRI scans. The patient information does not mention any contraindications or allergies to these contrasts. Therefore, we assume the patient can receive both types of contrast agents.\"\n    ],\n    \"criteria_decision\": [true]\n}\n```",
          "criteria_decision": {
            "explanation": [
              "The exclusion criterion states that the patient must be unable to receive both iodinated contrast for CT scans and gadolinium contrast for MRI scans. The patient information does not mention any contraindications or allergies to these contrasts. Therefore, we assume the patient can receive both types of contrast agents."
            ],
            "criteria_decision": [
              true
            ]
          }
        }
      ]
    ]
  },
  {
    "nctId": "NCT04685135",
    "avg_inclusion_score": 0.625,
    "avg_exclusion_score": 1.0,
    "avg_overall_score": 0.7857142857142857,
    "trial": {
      "clean_text": "#briefTitle\nPhase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation\n\n#officialTitle\nA Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation\n\n#briefSummary\nThis Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.\n\n#conditions\nMetastatic Non Small Cell Lung Cancer\nAdvanced Non Small Cell Lung Cancer\n\n",
      "briefTitle": "Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation",
      "officialTitle": "A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation",
      "briefSummary": "This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.",
      "detailedDescription": null,
      "conditions": [
        "Metastatic Non Small Cell Lung Cancer",
        "Advanced Non Small Cell Lung Cancer"
      ],
      "armGroups": [
        {
          "label": "MRTX849",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: MRTX849"
          ]
        },
        {
          "label": "Docetaxel",
          "type": "ACTIVE_COMPARATOR",
          "interventionNames": [
            "Drug: Docetaxel"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "MRTX849",
          "description": "21 day cycles",
          "armGroupLabels": [
            "MRTX849"
          ],
          "otherNames": [
            "adagrasib",
            "KRAZATI"
          ]
        },
        {
          "type": "DRUG",
          "name": "Docetaxel",
          "description": "21 day cycles",
          "armGroupLabels": [
            "Docetaxel"
          ],
          "otherNames": [
            "Taxotere"
          ]
        }
      ],
      "primaryOutcomes": [
        {
          "measure": "Progression-free Survival (PFS)",
          "description": "Defined as time from randomization until disease progression or death from any cause, whichever occurs first.",
          "timeFrame": "32 Months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Overall Survival (OS)",
          "description": "Defined as time from date of randomization to date of death due to any cause.",
          "timeFrame": "49 Months"
        },
        {
          "measure": "Objective Response Rate (ORR)",
          "description": "Defined as the percent of patients documented to have a confirmed CR or PR.",
          "timeFrame": "32 Months"
        },
        {
          "measure": "Duration of Response (DOR)",
          "description": "Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.",
          "timeFrame": "49 Months"
        },
        {
          "measure": "1-year Survival Rate",
          "timeFrame": "49 Months"
        },
        {
          "measure": "Safety",
          "description": "characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, laboratory abnormalities, and number of patients discontinuing study treatment due to an adverse event.",
          "timeFrame": "49 Months"
        },
        {
          "measure": "Population PK parameters of MRTX849",
          "description": "Data for this Outcome Measure will not be reported here but will be used in a Population PK Analysis which will include participants who were not enrolled in this study, and issued in a separate report. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules",
          "timeFrame": "49 Months"
        },
        {
          "measure": "Patient Reported Outcomes (PROs)",
          "description": "To be assessed by Lung Cancer Symptom Scale (LCSS).",
          "timeFrame": "49 Months"
        },
        {
          "measure": "Quality of LIfe Assessment",
          "description": "To be assessed by European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L).",
          "timeFrame": "49 Months"
        }
      ],
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.\n* Candidacy to receive treatment with docetaxel.\n\nCrossover Inclusion Criteria:\n\n* Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).\n* Active brain metastases.\n\nCrossover Exclusion Criteria:\n\n* Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.",
      "nctId": "NCT04685135",
      "overallStatus": "ACTIVE_NOT_RECRUITING",
      "keywords": [
        "KRAS G12C",
        "Non-small cell lung cancer",
        "NSCLC",
        "Metastatic Cancer",
        "Docetaxel",
        "Phase 3 Clinical Trial",
        "Adagrasib",
        "KRAS",
        "KRAZATI"
      ],
      "locations": [
        {
          "facility": "Research Site",
          "city": "Duarte",
          "state": "California",
          "zip": "91010",
          "country": "United States",
          "geoPoint": {
            "lat": 34.13945,
            "lon": -117.97729
          }
        },
        {
          "facility": "Research Site",
          "city": "Long Beach",
          "state": "California",
          "zip": "90813",
          "country": "United States",
          "geoPoint": {
            "lat": 33.76696,
            "lon": -118.18923
          }
        },
        {
          "facility": "Research Site",
          "city": "Santa Rosa",
          "state": "California",
          "zip": "95403",
          "country": "United States",
          "geoPoint": {
            "lat": 38.44047,
            "lon": -122.71443
          }
        },
        {
          "facility": "Research Site",
          "city": "Whittier",
          "state": "California",
          "zip": "90603",
          "country": "United States",
          "geoPoint": {
            "lat": 33.97918,
            "lon": -118.03284
          }
        },
        {
          "facility": "Research Site",
          "city": "Grand Junction",
          "state": "Colorado",
          "zip": "81502",
          "country": "United States",
          "geoPoint": {
            "lat": 39.06387,
            "lon": -108.55065
          }
        },
        {
          "facility": "Research Site",
          "city": "Lafayette",
          "state": "Colorado",
          "zip": "80026",
          "country": "United States",
          "geoPoint": {
            "lat": 39.9936,
            "lon": -105.08971
          }
        },
        {
          "facility": "Research Site",
          "city": "Lone Tree",
          "state": "Colorado",
          "zip": "80124",
          "country": "United States",
          "geoPoint": {
            "lat": 39.55171,
            "lon": -104.8863
          }
        },
        {
          "facility": "Research Site",
          "city": "Fort Lauderdale",
          "state": "Florida",
          "zip": "33308",
          "country": "United States",
          "geoPoint": {
            "lat": 26.12231,
            "lon": -80.14338
          }
        },
        {
          "facility": "Research Site",
          "city": "Jacksonville",
          "state": "Florida",
          "zip": "32204",
          "country": "United States",
          "geoPoint": {
            "lat": 30.33218,
            "lon": -81.65565
          }
        },
        {
          "facility": "Research Site",
          "city": "Jacksonville",
          "state": "Florida",
          "zip": "32256",
          "country": "United States",
          "geoPoint": {
            "lat": 30.33218,
            "lon": -81.65565
          }
        },
        {
          "facility": "Research Site",
          "city": "Miami Beach",
          "state": "Florida",
          "zip": "33140",
          "country": "United States",
          "geoPoint": {
            "lat": 25.79065,
            "lon": -80.13005
          }
        },
        {
          "facility": "Research Site",
          "city": "Orlando",
          "state": "Florida",
          "zip": "32806",
          "country": "United States",
          "geoPoint": {
            "lat": 28.53834,
            "lon": -81.37924
          }
        },
        {
          "facility": "Research Site",
          "city": "Plantation",
          "state": "Florida",
          "zip": "33322",
          "country": "United States",
          "geoPoint": {
            "lat": 26.13421,
            "lon": -80.23184
          }
        },
        {
          "facility": "Research Site",
          "city": "Athens",
          "state": "Georgia",
          "zip": "30607",
          "country": "United States",
          "geoPoint": {
            "lat": 33.96095,
            "lon": -83.37794
          }
        },
        {
          "facility": "Research Site",
          "city": "Marietta",
          "state": "Georgia",
          "zip": "30060",
          "country": "United States",
          "geoPoint": {
            "lat": 33.9526,
            "lon": -84.54993
          }
        },
        {
          "facility": "Research Site",
          "city": "Chicago",
          "state": "Illinois",
          "zip": "60612",
          "country": "United States",
          "geoPoint": {
            "lat": 41.85003,
            "lon": -87.65005
          }
        },
        {
          "facility": "Research Site",
          "city": "Chicago",
          "state": "Illinois",
          "zip": "60637",
          "country": "United States",
          "geoPoint": {
            "lat": 41.85003,
            "lon": -87.65005
          }
        },
        {
          "facility": "Research Site",
          "city": "Goshen",
          "state": "Indiana",
          "zip": "46526",
          "country": "United States",
          "geoPoint": {
            "lat": 41.58227,
            "lon": -85.83444
          }
        },
        {
          "facility": "Research Site",
          "city": "Indianapolis",
          "state": "Indiana",
          "zip": "46237",
          "country": "United States",
          "geoPoint": {
            "lat": 39.76838,
            "lon": -86.15804
          }
        },
        {
          "facility": "Research Site",
          "city": "Munster",
          "state": "Indiana",
          "zip": "46321",
          "country": "United States",
          "geoPoint": {
            "lat": 41.56448,
            "lon": -87.51254
          }
        },
        {
          "facility": "Research Site",
          "city": "Westwood",
          "state": "Kansas",
          "zip": "66205",
          "country": "United States",
          "geoPoint": {
            "lat": 39.04056,
            "lon": -94.6169
          }
        },
        {
          "facility": "Research Site",
          "city": "Wichita",
          "state": "Kansas",
          "zip": "67214",
          "country": "United States",
          "geoPoint": {
            "lat": 37.69224,
            "lon": -97.33754
          }
        },
        {
          "facility": "Research Site",
          "city": "New Orleans",
          "state": "Louisiana",
          "zip": "70112",
          "country": "United States",
          "geoPoint": {
            "lat": 29.95465,
            "lon": -90.07507
          }
        },
        {
          "facility": "Research Site",
          "city": "Scarborough",
          "state": "Maine",
          "zip": "04074",
          "country": "United States",
          "geoPoint": {
            "lat": 43.57814,
            "lon": -70.32172
          }
        },
        {
          "facility": "Research Site",
          "city": "Frederick",
          "state": "Maryland",
          "zip": "21702",
          "country": "United States",
          "geoPoint": {
            "lat": 39.41427,
            "lon": -77.41054
          }
        },
        {
          "facility": "Research Site",
          "city": "Billings",
          "state": "Montana",
          "zip": "59102",
          "country": "United States",
          "geoPoint": {
            "lat": 45.78329,
            "lon": -108.50069
          }
        },
        {
          "facility": "Research Site",
          "city": "East Brunswick",
          "state": "New Jersey",
          "zip": "08816",
          "country": "United States",
          "geoPoint": {
            "lat": 40.42788,
            "lon": -74.41598
          }
        },
        {
          "facility": "Research Site",
          "city": "Teaneck",
          "state": "New Jersey",
          "zip": "07666",
          "country": "United States",
          "geoPoint": {
            "lat": 40.8976,
            "lon": -74.01597
          }
        },
        {
          "facility": "Research Site",
          "city": "Syracuse",
          "state": "New York",
          "zip": "13210",
          "country": "United States",
          "geoPoint": {
            "lat": 43.04812,
            "lon": -76.14742
          }
        },
        {
          "facility": "Research Site",
          "city": "Cleveland",
          "state": "Ohio",
          "zip": "44106",
          "country": "United States",
          "geoPoint": {
            "lat": 41.4995,
            "lon": -81.69541
          }
        },
        {
          "facility": "Research Site",
          "city": "Kettering",
          "state": "Ohio",
          "zip": "45429",
          "country": "United States",
          "geoPoint": {
            "lat": 39.6895,
            "lon": -84.16883
          }
        },
        {
          "facility": "Research Site",
          "city": "Salem",
          "state": "Oregon",
          "zip": "97301",
          "country": "United States",
          "geoPoint": {
            "lat": 44.9429,
            "lon": -123.0351
          }
        },
        {
          "facility": "Research Site",
          "city": "Providence",
          "state": "Rhode Island",
          "zip": "02903",
          "country": "United States",
          "geoPoint": {
            "lat": 41.82399,
            "lon": -71.41283
          }
        },
        {
          "facility": "Research Site",
          "city": "Irving",
          "state": "Texas",
          "zip": "75063",
          "country": "United States",
          "geoPoint": {
            "lat": 32.81402,
            "lon": -96.94889
          }
        },
        {
          "facility": "Research Site",
          "city": "Bedford Park",
          "country": "Australia",
          "geoPoint": {
            "lat": -35.03333,
            "lon": 138.56667
          }
        },
        {
          "facility": "Research Site",
          "city": "Douglas",
          "country": "Australia",
          "geoPoint": {
            "lat": -37.03333,
            "lon": 141.73333
          }
        },
        {
          "facility": "Research Site",
          "city": "Heidelberg",
          "country": "Australia",
          "geoPoint": {
            "lat": -37.75,
            "lon": 145.06667
          }
        },
        {
          "facility": "Research Site",
          "city": "Mackay",
          "country": "Australia",
          "geoPoint": {
            "lat": -21.15345,
            "lon": 149.16554
          }
        },
        {
          "facility": "Research Site",
          "city": "Saint Leonards",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.82344,
            "lon": 151.19836
          }
        },
        {
          "facility": "Research Site",
          "city": "Tweed Heads",
          "country": "Australia",
          "geoPoint": {
            "lat": -28.17561,
            "lon": 153.54201
          }
        },
        {
          "facility": "Research Site",
          "city": "Wollongong",
          "country": "Australia",
          "geoPoint": {
            "lat": -34.424,
            "lon": 150.89345
          }
        },
        {
          "facility": "Research Site",
          "city": "Woolloongabba",
          "country": "Australia",
          "geoPoint": {
            "lat": -27.48855,
            "lon": 153.03655
          }
        },
        {
          "facility": "Research Site",
          "city": "Klagenfurt",
          "country": "Austria",
          "geoPoint": {
            "lat": 46.62472,
            "lon": 14.30528
          }
        },
        {
          "facility": "Research Site",
          "city": "Salzburg",
          "country": "Austria",
          "geoPoint": {
            "lat": 47.79941,
            "lon": 13.04399
          }
        },
        {
          "facility": "Research Site",
          "city": "Vienna",
          "country": "Austria",
          "geoPoint": {
            "lat": 48.20849,
            "lon": 16.37208
          }
        },
        {
          "facility": "Research Site",
          "city": "Brussels",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.85045,
            "lon": 4.34878
          }
        },
        {
          "facility": "Research Site",
          "city": "Charleroi",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.41136,
            "lon": 4.44448
          }
        },
        {
          "facility": "Research Site",
          "city": "Edegem",
          "country": "Belgium",
          "geoPoint": {
            "lat": 51.15662,
            "lon": 4.44504
          }
        },
        {
          "facility": "Research Site",
          "city": "Gent",
          "country": "Belgium",
          "geoPoint": {
            "lat": 51.05,
            "lon": 3.71667
          }
        },
        {
          "facility": "Research Site",
          "city": "Hasselt",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.93106,
            "lon": 5.33781
          }
        },
        {
          "facility": "Research Site",
          "city": "Roeselare",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.94653,
            "lon": 3.12269
          }
        },
        {
          "facility": "Research Site",
          "city": "Ronse",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.74574,
            "lon": 3.6005
          }
        },
        {
          "facility": "Research Site",
          "city": "Yvoir",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.3279,
            "lon": 4.88059
          }
        },
        {
          "facility": "Research Site",
          "city": "Beijing",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "Research Site",
          "city": "Changchun",
          "country": "China",
          "geoPoint": {
            "lat": 43.88,
            "lon": 125.32278
          }
        },
        {
          "facility": "Research Site",
          "city": "Changsha",
          "country": "China",
          "geoPoint": {
            "lat": 28.19874,
            "lon": 112.97087
          }
        },
        {
          "facility": "Research Site",
          "city": "Chengdu",
          "country": "China",
          "geoPoint": {
            "lat": 30.66667,
            "lon": 104.06667
          }
        },
        {
          "facility": "Research Site",
          "city": "Chongqing",
          "country": "China",
          "geoPoint": {
            "lat": 29.56278,
            "lon": 106.55278
          }
        },
        {
          "facility": "Research Site",
          "city": "Fuzhou",
          "country": "China",
          "geoPoint": {
            "lat": 26.06139,
            "lon": 119.30611
          }
        },
        {
          "facility": "Research Site",
          "city": "Guangxi",
          "country": "China"
        },
        {
          "facility": "Research Site",
          "city": "Guangzhou",
          "country": "China",
          "geoPoint": {
            "lat": 23.11667,
            "lon": 113.25
          }
        },
        {
          "facility": "Research Site",
          "city": "Hangzhou",
          "country": "China",
          "geoPoint": {
            "lat": 30.29365,
            "lon": 120.16142
          }
        },
        {
          "facility": "Research Site",
          "city": "Harbin",
          "country": "China",
          "geoPoint": {
            "lat": 45.75,
            "lon": 126.65
          }
        },
        {
          "facility": "Research Site",
          "city": "Jinan",
          "country": "China",
          "geoPoint": {
            "lat": 36.66833,
            "lon": 116.99722
          }
        },
        {
          "facility": "Research Site",
          "city": "Linyi",
          "country": "China",
          "geoPoint": {
            "lat": 35.06306,
            "lon": 118.34278
          }
        },
        {
          "facility": "Research Site",
          "city": "Nanchang",
          "country": "China",
          "geoPoint": {
            "lat": 28.68396,
            "lon": 115.85306
          }
        },
        {
          "facility": "Research Site",
          "city": "Nanjing",
          "country": "China",
          "geoPoint": {
            "lat": 32.06167,
            "lon": 118.77778
          }
        },
        {
          "facility": "Research Site",
          "city": "Qingdao",
          "country": "China",
          "geoPoint": {
            "lat": 36.06488,
            "lon": 120.38042
          }
        },
        {
          "facility": "Research Site",
          "city": "Shanghai",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        },
        {
          "facility": "Research Site",
          "city": "Shenyang",
          "country": "China",
          "geoPoint": {
            "lat": 41.79222,
            "lon": 123.43278
          }
        },
        {
          "facility": "Research Site",
          "city": "Wuhan",
          "country": "China",
          "geoPoint": {
            "lat": 30.58333,
            "lon": 114.26667
          }
        },
        {
          "facility": "Research Site",
          "city": "Xiamen",
          "country": "China",
          "geoPoint": {
            "lat": 24.47979,
            "lon": 118.08187
          }
        },
        {
          "facility": "Research Site",
          "city": "Xinxiang",
          "country": "China",
          "geoPoint": {
            "lat": 35.19033,
            "lon": 113.80151
          }
        },
        {
          "facility": "Research Site",
          "city": "Xuzhou",
          "country": "China",
          "geoPoint": {
            "lat": 34.18045,
            "lon": 117.15707
          }
        },
        {
          "facility": "Research Site",
          "city": "Zhengzhou",
          "country": "China",
          "geoPoint": {
            "lat": 34.75778,
            "lon": 113.64861
          }
        },
        {
          "facility": "Research SIte",
          "city": "Ho\u0159ovice",
          "country": "Czechia",
          "geoPoint": {
            "lat": 49.83597,
            "lon": 13.90268
          }
        },
        {
          "facility": "Research Site",
          "city": "Olomouc",
          "country": "Czechia",
          "geoPoint": {
            "lat": 49.59552,
            "lon": 17.25175
          }
        },
        {
          "facility": "Research Site",
          "city": "Prague",
          "country": "Czechia",
          "geoPoint": {
            "lat": 50.08804,
            "lon": 14.42076
          }
        },
        {
          "facility": "Research Site",
          "city": "Praha 2",
          "country": "Czechia",
          "geoPoint": {
            "lat": 50.08804,
            "lon": 14.42076
          }
        },
        {
          "facility": "Research Site",
          "city": "Brest",
          "country": "France",
          "geoPoint": {
            "lat": 48.3903,
            "lon": -4.48628
          }
        },
        {
          "facility": "Research Site",
          "city": "Bron",
          "country": "France",
          "geoPoint": {
            "lat": 45.73333,
            "lon": 4.91667
          }
        },
        {
          "facility": "Research Site",
          "city": "Caen",
          "country": "France",
          "geoPoint": {
            "lat": 49.18585,
            "lon": -0.35912
          }
        },
        {
          "facility": "Research Site",
          "city": "Cr\u00e9teil",
          "country": "France",
          "geoPoint": {
            "lat": 48.78333,
            "lon": 2.46667
          }
        },
        {
          "facility": "Research Site",
          "city": "Dijon Cedex",
          "country": "France",
          "geoPoint": {
            "lat": 47.31667,
            "lon": 5.01667
          }
        },
        {
          "facility": "Research Site",
          "city": "Gleiz\u00e9",
          "country": "France",
          "geoPoint": {
            "lat": 45.99082,
            "lon": 4.70071
          }
        },
        {
          "facility": "Research Site",
          "city": "La Tronche",
          "country": "France",
          "geoPoint": {
            "lat": 45.20429,
            "lon": 5.73645
          }
        },
        {
          "facility": "Research Site",
          "city": "Limoges cedex",
          "country": "France",
          "geoPoint": {
            "lat": 45.83153,
            "lon": 1.25781
          }
        },
        {
          "facility": "Research Site",
          "city": "Marseille",
          "country": "France",
          "geoPoint": {
            "lat": 43.29551,
            "lon": 5.38958
          }
        },
        {
          "facility": "Research Site",
          "city": "Montpellier",
          "country": "France",
          "geoPoint": {
            "lat": 43.61092,
            "lon": 3.87723
          }
        },
        {
          "facility": "Research Site",
          "city": "Mulhouse",
          "country": "France",
          "geoPoint": {
            "lat": 47.75,
            "lon": 7.33333
          }
        },
        {
          "facility": "Research Site",
          "city": "Nice",
          "country": "France",
          "geoPoint": {
            "lat": 43.70313,
            "lon": 7.26608
          }
        },
        {
          "facility": "Research Site",
          "city": "Quimper",
          "country": "France",
          "geoPoint": {
            "lat": 48.0,
            "lon": -4.1
          }
        },
        {
          "facility": "Research Site",
          "city": "Saint Herblain",
          "country": "France",
          "geoPoint": {
            "lat": 47.21765,
            "lon": -1.64841
          }
        },
        {
          "facility": "Research Site",
          "city": "Saint-Priest-en-Jarez",
          "country": "France",
          "geoPoint": {
            "lat": 45.47501,
            "lon": 4.37614
          }
        },
        {
          "facility": "Research Site",
          "city": "Strasbourg",
          "country": "France",
          "geoPoint": {
            "lat": 48.58392,
            "lon": 7.74553
          }
        },
        {
          "facility": "Research Site",
          "city": "Tours Cedex 9",
          "country": "France",
          "geoPoint": {
            "lat": 47.38333,
            "lon": 0.68333
          }
        },
        {
          "facility": "Research Site",
          "city": "Villejuif",
          "country": "France",
          "geoPoint": {
            "lat": 48.7939,
            "lon": 2.35992
          }
        },
        {
          "facility": "Research Site",
          "city": "M\u00fcnchen",
          "state": "Bayern",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.13743,
            "lon": 11.57549
          }
        },
        {
          "facility": "Research Site",
          "city": "Bad Berka",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.89982,
            "lon": 11.28245
          }
        },
        {
          "facility": "Research Site",
          "city": "Bonn",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.73438,
            "lon": 7.09549
          }
        },
        {
          "facility": "Research Site",
          "city": "Essen",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.45657,
            "lon": 7.01228
          }
        },
        {
          "facility": "Research site",
          "city": "Gauting",
          "country": "Germany",
          "geoPoint": {
            "lat": 48.06919,
            "lon": 11.37703
          }
        },
        {
          "facility": "Research Site",
          "city": "Gie\u00dfen",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.58727,
            "lon": 8.67554
          }
        },
        {
          "facility": "Research Site",
          "city": "Gro\u00dfhansdorf",
          "country": "Germany",
          "geoPoint": {
            "lat": 53.66667,
            "lon": 10.28333
          }
        },
        {
          "facility": "Research Site",
          "city": "Halle (Saale)",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.48159,
            "lon": 11.97948
          }
        },
        {
          "facility": "Research Site",
          "city": "Jena",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.92878,
            "lon": 11.5899
          }
        },
        {
          "facility": "Research Site",
          "city": "Kassel",
          "country": "Germany",
          "geoPoint": {
            "lat": 51.31667,
            "lon": 9.5
          }
        },
        {
          "facility": "Research Site",
          "city": "K\u00f6ln",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.93333,
            "lon": 6.95
          }
        },
        {
          "facility": "Research Site",
          "city": "L\u00f6wenstein",
          "country": "Germany",
          "geoPoint": {
            "lat": 49.0954,
            "lon": 9.38069
          }
        },
        {
          "facility": "Research Site",
          "city": "L\u00fcbeck",
          "country": "Germany",
          "geoPoint": {
            "lat": 53.86893,
            "lon": 10.68729
          }
        },
        {
          "facility": "Research Site",
          "city": "Offenbach",
          "country": "Germany",
          "geoPoint": {
            "lat": 50.10061,
            "lon": 8.76647
          }
        },
        {
          "facility": "Research Site",
          "city": "Oldenburg",
          "country": "Germany",
          "geoPoint": {
            "lat": 53.14118,
            "lon": 8.21467
          }
        },
        {
          "facility": "Research Site",
          "city": "Athens",
          "country": "Greece",
          "geoPoint": {
            "lat": 37.97945,
            "lon": 23.71622
          }
        },
        {
          "facility": "Research Site",
          "city": "Heraklion",
          "country": "Greece",
          "geoPoint": {
            "lat": 35.32787,
            "lon": 25.14341
          }
        },
        {
          "facility": "Research Site",
          "city": "Larissa",
          "country": "Greece",
          "geoPoint": {
            "lat": 39.63689,
            "lon": 22.41761
          }
        },
        {
          "facility": "Research Site",
          "city": "N\u00e9a Kifisi\u00e1",
          "country": "Greece",
          "geoPoint": {
            "lat": 38.09282,
            "lon": 23.80192
          }
        },
        {
          "facility": "Research Site",
          "city": "N\u00e9o F\u00e1liro",
          "country": "Greece",
          "geoPoint": {
            "lat": 37.9464,
            "lon": 23.66736
          }
        },
        {
          "facility": "Research Site",
          "city": "Thessalon\u00edki",
          "country": "Greece",
          "geoPoint": {
            "lat": 40.64361,
            "lon": 22.93086
          }
        },
        {
          "facility": "Research Site",
          "city": "Volos",
          "country": "Greece",
          "geoPoint": {
            "lat": 39.36103,
            "lon": 22.94248
          }
        },
        {
          "facility": "Research Site",
          "city": "Hong Kong",
          "country": "Hong Kong",
          "geoPoint": {
            "lat": 22.27832,
            "lon": 114.17469
          }
        },
        {
          "facility": "Research Site",
          "city": "Kowloon",
          "country": "Hong Kong",
          "geoPoint": {
            "lat": 22.31667,
            "lon": 114.18333
          }
        },
        {
          "facility": "Research Site",
          "city": "Shatin",
          "country": "Hong Kong",
          "geoPoint": {
            "lat": 22.38333,
            "lon": 114.18333
          }
        },
        {
          "facility": "Research Site",
          "city": "Budapest",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.49801,
            "lon": 19.03991
          }
        },
        {
          "facility": "Research Site",
          "city": "Gyula",
          "country": "Hungary",
          "geoPoint": {
            "lat": 46.65,
            "lon": 21.28333
          }
        },
        {
          "facility": "Research Site",
          "city": "Gy\u00f6ngy\u00f6s",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.78257,
            "lon": 19.928
          }
        },
        {
          "facility": "Research Site",
          "city": "Sz\u00e9kesfeh\u00e9rv\u00e1r",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.18995,
            "lon": 18.41034
          }
        },
        {
          "facility": "Research Site",
          "city": "T\u00f6r\u00f6kb\u00e1lint",
          "country": "Hungary",
          "geoPoint": {
            "lat": 47.42931,
            "lon": 18.91356
          }
        },
        {
          "facility": "Research Site",
          "city": "Dublin",
          "country": "Ireland",
          "geoPoint": {
            "lat": 53.33306,
            "lon": -6.24889
          }
        },
        {
          "facility": "Research Site",
          "city": "Galway",
          "country": "Ireland",
          "geoPoint": {
            "lat": 53.27194,
            "lon": -9.04889
          }
        },
        {
          "facility": "Research Site",
          "city": "Limerick",
          "country": "Ireland",
          "geoPoint": {
            "lat": 52.66472,
            "lon": -8.62306
          }
        },
        {
          "facility": "Research Site",
          "city": "Alessandria",
          "country": "Italy",
          "geoPoint": {
            "lat": 44.90924,
            "lon": 8.61007
          }
        },
        {
          "facility": "Research Site",
          "city": "Avellino",
          "country": "Italy",
          "geoPoint": {
            "lat": 40.91494,
            "lon": 14.79103
          }
        },
        {
          "facility": "Research Site",
          "city": "Aviano",
          "country": "Italy",
          "geoPoint": {
            "lat": 46.07056,
            "lon": 12.59472
          }
        },
        {
          "facility": "Research Site",
          "city": "Bari",
          "country": "Italy",
          "geoPoint": {
            "lat": 41.11148,
            "lon": 16.8554
          }
        },
        {
          "facility": "Research Site",
          "city": "Brescia",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.53558,
            "lon": 10.21472
          }
        },
        {
          "facility": "Research Site",
          "city": "Candiolo",
          "country": "Italy",
          "geoPoint": {
            "lat": 44.95858,
            "lon": 7.59812
          }
        },
        {
          "facility": "Research Site",
          "city": "Catania",
          "country": "Italy",
          "geoPoint": {
            "lat": 37.49223,
            "lon": 15.07041
          }
        },
        {
          "facility": "Research Site",
          "city": "Firenze",
          "country": "Italy",
          "geoPoint": {
            "lat": 43.77925,
            "lon": 11.24626
          }
        },
        {
          "facility": "Research Site",
          "city": "Genova",
          "country": "Italy",
          "geoPoint": {
            "lat": 44.40478,
            "lon": 8.94438
          }
        },
        {
          "facility": "Research Site",
          "city": "Lecce",
          "country": "Italy",
          "geoPoint": {
            "lat": 40.35481,
            "lon": 18.17244
          }
        },
        {
          "facility": "Research Site",
          "city": "Meldola",
          "country": "Italy",
          "geoPoint": {
            "lat": 44.12775,
            "lon": 12.0626
          }
        },
        {
          "facility": "Research Site",
          "city": "Milano",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Research Site",
          "city": "Milan",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.46427,
            "lon": 9.18951
          }
        },
        {
          "facility": "Research Site",
          "city": "Napoli",
          "country": "Italy",
          "geoPoint": {
            "lat": 40.85216,
            "lon": 14.26811
          }
        },
        {
          "facility": "Research Site",
          "city": "Novara",
          "country": "Italy",
          "geoPoint": {
            "lat": 45.44694,
            "lon": 8.62118
          }
        },
        {
          "facility": "Research Site",
          "city": "Parma",
          "country": "Italy",
          "geoPoint": {
            "lat": 44.79935,
            "lon": 10.32618
          }
        },
        {
          "facility": "Research Site",
          "city": "Perugia",
          "country": "Italy",
          "geoPoint": {
            "lat": 43.1122,
            "lon": 12.38878
          }
        },
        {
          "facility": "Research Site",
          "city": "Pesaro",
          "country": "Italy",
          "geoPoint": {
            "lat": 43.90921,
            "lon": 12.9164
          }
        },
        {
          "facility": "Research Site",
          "city": "Ravenna",
          "country": "Italy",
          "geoPoint": {
            "lat": 44.41344,
            "lon": 12.20121
          }
        },
        {
          "facility": "Research Site",
          "city": "Roma",
          "country": "Italy",
          "geoPoint": {
            "lat": 41.89193,
            "lon": 12.51133
          }
        },
        {
          "facility": "Research Site",
          "city": "Busan",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 35.10278,
            "lon": 129.04028
          }
        },
        {
          "facility": "Research Site",
          "city": "Cheongju-si",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 36.63722,
            "lon": 127.48972
          }
        },
        {
          "facility": "Research Site",
          "city": "Daegu",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 35.87028,
            "lon": 128.59111
          }
        },
        {
          "facility": "Research Site",
          "city": "Hwasun",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 35.06125,
            "lon": 126.98746
          }
        },
        {
          "facility": "Research Site",
          "city": "Incheon",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.45646,
            "lon": 126.70515
          }
        },
        {
          "facility": "Research Site",
          "city": "Seongnam-si",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.43861,
            "lon": 127.13778
          }
        },
        {
          "facility": "Research Site",
          "city": "Seoul",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.566,
            "lon": 126.9784
          }
        },
        {
          "facility": "Research Site",
          "city": "Suwon-si",
          "country": "Korea, Republic of",
          "geoPoint": {
            "lat": 37.29111,
            "lon": 127.00889
          }
        },
        {
          "facility": "Research Site",
          "city": "Amsterdam",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.37403,
            "lon": 4.88969
          }
        },
        {
          "facility": "Research Site",
          "city": "Breda",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 51.58656,
            "lon": 4.77596
          }
        },
        {
          "facility": "Research Site",
          "city": "Den Haag",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.07667,
            "lon": 4.29861
          }
        },
        {
          "facility": "Research Site",
          "city": "Maastricht",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 50.84833,
            "lon": 5.68889
          }
        },
        {
          "facility": "Research Site",
          "city": "Nieuwegein",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.02917,
            "lon": 5.08056
          }
        },
        {
          "facility": "Research Site",
          "city": "Nijmegen",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 51.8425,
            "lon": 5.85278
          }
        },
        {
          "facility": "Research Site",
          "city": "Utrecht",
          "country": "Netherlands",
          "geoPoint": {
            "lat": 52.09083,
            "lon": 5.12222
          }
        },
        {
          "facility": "Research Site",
          "city": "Lublin",
          "state": "Lubelskie",
          "country": "Poland",
          "geoPoint": {
            "lat": 51.25,
            "lon": 22.56667
          }
        },
        {
          "facility": "Research Site",
          "city": "Lublin",
          "country": "Poland",
          "geoPoint": {
            "lat": 51.25,
            "lon": 22.56667
          }
        },
        {
          "facility": "Research Site",
          "city": "Otwock",
          "country": "Poland",
          "geoPoint": {
            "lat": 52.10577,
            "lon": 21.26129
          }
        },
        {
          "facility": "Research Site",
          "city": "Rzesz\u00f3w",
          "country": "Poland",
          "geoPoint": {
            "lat": 50.04132,
            "lon": 21.99901
          }
        },
        {
          "facility": "Research Site",
          "city": "Skorzewo",
          "country": "Poland"
        },
        {
          "facility": "Research Site",
          "city": "Toru\u0144",
          "country": "Poland",
          "geoPoint": {
            "lat": 53.01375,
            "lon": 18.59814
          }
        },
        {
          "facility": "Research Site",
          "city": "Warszawa",
          "country": "Poland",
          "geoPoint": {
            "lat": 52.22977,
            "lon": 21.01178
          }
        },
        {
          "facility": "Research Site",
          "city": "\u0141\u00f3d\u017a",
          "country": "Poland",
          "geoPoint": {
            "lat": 51.75,
            "lon": 19.46667
          }
        },
        {
          "facility": "Research Site",
          "city": "Almada",
          "country": "Portugal",
          "geoPoint": {
            "lat": 38.67902,
            "lon": -9.1569
          }
        },
        {
          "facility": "Research Site",
          "city": "Braga",
          "country": "Portugal",
          "geoPoint": {
            "lat": 41.55032,
            "lon": -8.42005
          }
        },
        {
          "facility": "Research Site",
          "city": "Coimbra",
          "country": "Portugal",
          "geoPoint": {
            "lat": 40.20564,
            "lon": -8.41955
          }
        },
        {
          "facility": "Research Site",
          "city": "Guimar\u00e3es",
          "country": "Portugal",
          "geoPoint": {
            "lat": 41.44443,
            "lon": -8.29619
          }
        },
        {
          "facility": "Research Site",
          "city": "Lisboa",
          "country": "Portugal",
          "geoPoint": {
            "lat": 38.71667,
            "lon": -9.13333
          }
        },
        {
          "facility": "Research Site",
          "city": "Lisbon",
          "country": "Portugal",
          "geoPoint": {
            "lat": 38.71667,
            "lon": -9.13333
          }
        },
        {
          "facility": "Research Site",
          "city": "Loures",
          "country": "Portugal",
          "geoPoint": {
            "lat": 38.83091,
            "lon": -9.16845
          }
        },
        {
          "facility": "Research Site",
          "city": "Porto",
          "country": "Portugal",
          "geoPoint": {
            "lat": 41.14961,
            "lon": -8.61099
          }
        },
        {
          "facility": "Research Site",
          "city": "Santa Maria Da Feira",
          "country": "Portugal",
          "geoPoint": {
            "lat": 40.92726,
            "lon": -8.54839
          }
        },
        {
          "facility": "Research Site",
          "city": "Set\u00fabal",
          "country": "Portugal",
          "geoPoint": {
            "lat": 38.5244,
            "lon": -8.8882
          }
        },
        {
          "facility": "Research Site",
          "city": "Vila Nova De Gaia",
          "country": "Portugal",
          "geoPoint": {
            "lat": 41.13363,
            "lon": -8.61742
          }
        },
        {
          "facility": "Research Site",
          "city": "Baia Mare",
          "country": "Romania",
          "geoPoint": {
            "lat": 47.65529,
            "lon": 23.57381
          }
        },
        {
          "facility": "Research Site",
          "city": "Bra\u015fov",
          "country": "Romania",
          "geoPoint": {
            "lat": 45.64861,
            "lon": 25.60613
          }
        },
        {
          "facility": "Research Site",
          "city": "Bucharest",
          "country": "Romania",
          "geoPoint": {
            "lat": 44.43225,
            "lon": 26.10626
          }
        },
        {
          "facility": "Research Site",
          "city": "Bucuresti",
          "country": "Romania",
          "geoPoint": {
            "lat": 44.42802,
            "lon": 26.09665
          }
        },
        {
          "facility": "Research Site",
          "city": "Cluj-Napoca",
          "country": "Romania",
          "geoPoint": {
            "lat": 46.76667,
            "lon": 23.6
          }
        },
        {
          "facility": "Research Site",
          "city": "Constan\u0163a",
          "country": "Romania",
          "geoPoint": {
            "lat": 44.18073,
            "lon": 28.63432
          }
        },
        {
          "facility": "Research Site",
          "city": "Craiova",
          "country": "Romania",
          "geoPoint": {
            "lat": 44.31667,
            "lon": 23.8
          }
        },
        {
          "facility": "Research Site",
          "city": "Ia\u015fi",
          "country": "Romania",
          "geoPoint": {
            "lat": 47.16667,
            "lon": 27.6
          }
        },
        {
          "facility": "Research Site",
          "city": "Timi\u015foara",
          "country": "Romania",
          "geoPoint": {
            "lat": 45.75372,
            "lon": 21.22571
          }
        },
        {
          "facility": "Research Site",
          "city": "Chelyabinsk",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 55.15402,
            "lon": 61.42915
          }
        },
        {
          "facility": "Research Site",
          "city": "Izhevsk",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 56.84976,
            "lon": 53.20448
          }
        },
        {
          "facility": "Research Site",
          "city": "Kursk",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 51.73733,
            "lon": 36.18735
          }
        },
        {
          "facility": "Research Site",
          "city": "Moscow",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 55.75222,
            "lon": 37.61556
          }
        },
        {
          "facility": "Research Site",
          "city": "Nizhniy Novgorod",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 56.32867,
            "lon": 44.00205
          }
        },
        {
          "facility": "Research Site",
          "city": "Novosibirsk",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 55.0415,
            "lon": 82.9346
          }
        },
        {
          "facility": "Research Site",
          "city": "Omsk",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 54.99244,
            "lon": 73.36859
          }
        },
        {
          "facility": "Research Site",
          "city": "Saint Petersburg",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 59.93863,
            "lon": 30.31413
          }
        },
        {
          "facility": "Research Site",
          "city": "Saint-Petersburg",
          "country": "Russian Federation",
          "geoPoint": {
            "lat": 59.93863,
            "lon": 30.31413
          }
        },
        {
          "facility": "Research Site",
          "city": "Singapore",
          "country": "Singapore",
          "geoPoint": {
            "lat": 1.28967,
            "lon": 103.85007
          }
        },
        {
          "facility": "Research Site",
          "city": "A Coru\u00f1a",
          "country": "Spain",
          "geoPoint": {
            "lat": 43.37135,
            "lon": -8.396
          }
        },
        {
          "facility": "Research Site",
          "city": "Alicante",
          "country": "Spain",
          "geoPoint": {
            "lat": 38.34517,
            "lon": -0.48149
          }
        },
        {
          "facility": "Research Site",
          "city": "Badalona",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.45004,
            "lon": 2.24741
          }
        },
        {
          "facility": "Research Site",
          "city": "Barakaldo",
          "country": "Spain",
          "geoPoint": {
            "lat": 43.29639,
            "lon": -2.98813
          }
        },
        {
          "facility": "Research Site",
          "city": "Barcelona",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Research Site",
          "city": "Cordoba",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.89155,
            "lon": -4.77275
          }
        },
        {
          "facility": "Research Site",
          "city": "Girona",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.98311,
            "lon": 2.82493
          }
        },
        {
          "facility": "Research Site",
          "city": "Granada",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.18817,
            "lon": -3.60667
          }
        },
        {
          "facility": "Research Site",
          "city": "Le\u00f3n",
          "country": "Spain",
          "geoPoint": {
            "lat": 42.60003,
            "lon": -5.57032
          }
        },
        {
          "facility": "Research Site",
          "city": "Lugo",
          "country": "Spain",
          "geoPoint": {
            "lat": 43.00992,
            "lon": -7.55602
          }
        },
        {
          "facility": "Research Site",
          "city": "Madrid",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Research Site",
          "city": "Malaga",
          "country": "Spain",
          "geoPoint": {
            "lat": 36.72016,
            "lon": -4.42034
          }
        },
        {
          "facility": "Research Site",
          "city": "Palma De Mallorca",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.56939,
            "lon": 2.65024
          }
        },
        {
          "facility": "Research Site",
          "city": "Santander",
          "country": "Spain",
          "geoPoint": {
            "lat": 43.46472,
            "lon": -3.80444
          }
        },
        {
          "facility": "Research Site",
          "city": "Sevilla",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.38283,
            "lon": -5.97317
          }
        },
        {
          "facility": "Research Site",
          "city": "Valencia",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.46975,
            "lon": -0.37739
          }
        },
        {
          "facility": "Research Site",
          "city": "Zaragoza",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.65606,
            "lon": -0.87734
          }
        },
        {
          "facility": "Research Site",
          "city": "Basel",
          "country": "Switzerland",
          "geoPoint": {
            "lat": 47.55839,
            "lon": 7.57327
          }
        },
        {
          "facility": "Research Site",
          "city": "Thun",
          "country": "Switzerland",
          "geoPoint": {
            "lat": 46.75118,
            "lon": 7.62166
          }
        },
        {
          "facility": "Research Site",
          "city": "Winterthur",
          "country": "Switzerland",
          "geoPoint": {
            "lat": 47.50564,
            "lon": 8.72413
          }
        },
        {
          "facility": "Research Site",
          "city": "Birmingham",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 52.48142,
            "lon": -1.89983
          }
        },
        {
          "facility": "Research Site",
          "city": "Edinburgh",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 55.95206,
            "lon": -3.19648
          }
        },
        {
          "facility": "Research Site",
          "city": "Glasgow",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 55.86515,
            "lon": -4.25763
          }
        },
        {
          "facility": "Research Site",
          "city": "Leicester",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 52.6386,
            "lon": -1.13169
          }
        },
        {
          "facility": "Research Site",
          "city": "Manchester",
          "country": "United Kingdom",
          "geoPoint": {
            "lat": 53.48095,
            "lon": -2.23743
          }
        }
      ],
      "eligibilityModule": {
        "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.\n* Candidacy to receive treatment with docetaxel.\n\nCrossover Inclusion Criteria:\n\n* Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).\n* Active brain metastases.\n\nCrossover Exclusion Criteria:\n\n* Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.",
        "healthyVolunteers": false,
        "sex": "ALL",
        "minimumAge": "18 Years",
        "stdAges": [
          "ADULT",
          "OLDER_ADULT"
        ]
      },
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ]
    },
    "structured_criteria": {
      "inclusion": {
        "Inclusion Criteria:": [
          "Patients who meet all of the following criteria are eligible for trial participation: ",
          [
            "* Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.",
            "* Candidacy to receive treatment with docetaxel."
          ]
        ],
        "Crossover Inclusion Criteria:": [
          "Patients who meet all of the following criteria are eligible for trial participation: ",
          [
            "* Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR",
            "* ECOG performance status 0-2"
          ]
        ]
      },
      "exclusion": {
        "Exclusion Criteria:": [
          "Patients who meet any of the following criteria are not eligible for trial participation: ",
          [
            "* Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).",
            "* Active brain metastases."
          ]
        ],
        "Crossover Exclusion Criteria:": [
          "Patients who meet any of the following criteria are not eligible for trial participation: ",
          [
            "* Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study."
          ]
        ]
      }
    },
    "results_inclusion": [
      [
        "Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "* Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.",
          "* Candidacy to receive treatment with docetaxel."
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each criterion independently based on the provided patient information.\n\n1. **Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.**\n   - The patient information explicitly states that the patient has a diagnosis of metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC).\n   - Therefore, the patient meets this criterion.\n   - Decision: **True**\n\n2. **Candidacy to receive treatment with docetaxel.**\n   - The patient information does not explicitly mention whether the patient is a candidate for docetaxel treatment.\n   - There is no information provided about any contraindications or previous adverse reactions to docetaxel.\n   - Therefore, the information is not sufficient to make a decision.\n   - Decision: **?**",
          "criteria_decision": {
            "explanation": [
              "The patient has a histologically confirmed diagnosis of NSCLC with a KRAS G12C mutation, meeting the first criterion.",
              "There is no information provided about the patient's candidacy to receive treatment with docetaxel, so the decision is '?'."
            ],
            "criteria_decision": [
              true,
              "?"
            ]
          }
        }
      ],
      [
        "Crossover Inclusion Criteria:",
        "Patients who meet all of the following criteria are eligible for trial participation: ",
        [
          "* Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR",
          "* ECOG performance status 0-2"
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each criterion independently based on the provided patient information.\n\n1. **Criterion: Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR**\n   - The patient information does not mention any treatment with docetaxel. The treatments listed include chemotherapy with Cisplatin and Pemetrexed, followed by immunotherapy with Pembrolizumab.\n   - Since there is no mention of docetaxel treatment, we assume the patient has not been treated with docetaxel.\n   - **Decision: False** (The patient does not meet this criterion as there is no evidence of disease progression on docetaxel.)\n\n2. **Criterion: ECOG performance status 0-2**\n   - The patient information explicitly states that the current ECOG performance status is 1.\n   - **Decision: True** (The patient meets this criterion as the ECOG performance status is within the required range.)",
          "criteria_decision": {
            "explanation": [
              "The patient has not been treated with docetaxel, so there is no evidence of RECIST 1.1 defined disease progression on docetaxel per BICR.",
              "The patient's ECOG performance status is 1, which is within the required range of 0-2."
            ],
            "criteria_decision": [
              false,
              true
            ]
          }
        }
      ]
    ],
    "results_exclusion": [
      [
        "Exclusion Criteria:",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).",
          "* Active brain metastases."
        ],
        {
          "reasoning": "Reasoning: Let's think step by step in order to produce the criteria_decision. We will evaluate each exclusion criterion based on the provided patient information.\n\n1. **Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib):**\n   - The patient information does not mention any prior treatment with an agent targeting KRAS G12C. The treatments listed include chemotherapy (Cisplatin and Pemetrexed) and immunotherapy (Pembrolizumab). Therefore, we assume the patient has not received any KRAS G12C targeting agents.\n   - Decision: True\n\n2. **Active brain metastases:**\n   - The patient information includes an MRI scan of the brain conducted on March 12, 2024, which showed no evidence of metastatic disease. Therefore, the patient does not have active brain metastases.\n   - Decision: True",
          "criteria_decision": {
            "explanation": [
              "The patient has not received any prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).",
              "The MRI scan of the brain conducted on March 12, 2024, showed no evidence of metastatic disease."
            ],
            "criteria_decision": [
              true,
              true
            ]
          }
        }
      ],
      [
        "Crossover Exclusion Criteria:",
        "Patients who meet any of the following criteria are not eligible for trial participation: ",
        [
          "* Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study."
        ],
        {
          "reasoning": "```json\n{\n    \"explanation\": [\n        \"The exclusion criterion states that the patient should not have received any other systemic anti-cancer therapy after the last administration of docetaxel on the study. The patient information does not mention the administration of docetaxel at any point. Therefore, it can be assumed that the patient has not received docetaxel, and thus the criterion does not apply. Hence, the patient is eligible based on this criterion.\"\n    ],\n    \"criteria_decision\": [true]\n}\n```",
          "criteria_decision": {
            "explanation": [
              "The exclusion criterion states that the patient should not have received any other systemic anti-cancer therapy after the last administration of docetaxel on the study. The patient information does not mention the administration of docetaxel at any point. Therefore, it can be assumed that the patient has not received docetaxel, and thus the criterion does not apply. Hence, the patient is eligible based on this criterion."
            ],
            "criteria_decision": [
              true
            ]
          }
        }
      ]
    ]
  }
]